Mechanisms of High Insulin and High Glucose-Induced Skeletal Muscle Insulin Resistance: Focus on Regulation by Adiponectin by Ahlstrom, Penny Felicia Ulrika
MECHANISMS OF HIGH INSULIN AND HIGH GLUCOSE-
INDUCED SKELETAL MUSCLE INSULIN RESISTANCE: 
FOCUS ON REGULATION BY ADIPONECTIN 
 
Penny Felicia Ulrika Ahlstrom 
 
 
A THESIS SUBMITTED TO  
THE FACULTY OF GRADUATE STUDIES  
IN PARTIAL FULFILLMENT OF THE REQUIREMENTS  
FOR THE DEGREE OF  
MASTER OF SCIENCE 
 
 
Graduate Program in Biology 
York University 
Toronto, Ontario 
 
September 2015 
 
 
© Penny Felicia Ulrika Ahlstrom, 2015  
Abstract 
Skeletal muscle insulin resistance is known to play an important role in the pathogenesis 
of diabetes, however the cellular processes involved are poorly defined. Autophagy, ER stress, 
the UPR and oxidative stress are being studied in insulin resistance but the exact role they play 
and their interrelationships are yet to be established. Adiponectin is a known insulin sensitizer 
with anti-diabetic properties but there is limited knowledge of the mechanism by which it exerts 
its insulin sensitizing effect in skeletal muscle. Through several well-established assays I have 
demonstrated that impaired autophagy caused ER stress and that UPR activation, specifically 
peIf2α, activated autophagy. Adiponectin alleviated ER stress by restoring autophagy, and a 
correlation between autophagy induction and insulin sensitization by adiponectin was observed. 
Alleviating oxidative stress with NAC improved insulin sensitivity independent of ER stress and 
autophagy, and there appeared to be a correlation between downregulating the UPR and 
improved insulin sensitivity. 
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Chapter 1. Introduction 
1.1 Diabetes: a Global Health Epidemic 
1.1.1 Diabetes Mellitus 
Diabetes Mellitus is a chronic metabolic disorder hallmarked by a dysregulation of whole 
body glucose homeostasis resulting in glucose intolerance and hyperglycemia, causing serious 
health complications including kidney failure, heart disease, stroke, nerve damage, and 
blindness [1]. There are two main types of diabetes, type 1 and type 2. Type 1 diabetes is a 
chronic autoimmune disease, typically with onset in younger individuals, characterized by an 
inability to produce insulin due to the destruction of pancreatic beta-cells. Type 1 diabetes 
accounts for approximately 5-10% of all diabetes cases [1, 2]. Conversely, type 2 diabetes is the 
result of insulin resistance in peripheral tissues such as muscle, liver and adipose. Diminished 
response to normal levels of insulin prompts an increase in production of insulin from beta-cells 
to control blood glucose levels, eventually leading to diminished beta-cell function and 
exogenous insulin dependency [3]. Type 2 diabetes corresponds to 90-95% of all diabetes 
cases and is the focus of my research (hereafter simply referred to as diabetes) [2, 4]. 
1.1.2 Obesity and Diabetes Prevalence 
A change over the last few decades to a sedentary life-style coupled with a high calorie 
diet has led to a staggering increase in obesity prevalence [5]. In 2005, the global obese 
population was estimated at 396 million, and with the current trend continuing the projected 
number of obese people in the world is expected to rise to 1.12 billion in 2030. This represents a 
rise in world-wide obesity prevalence from 9.8% in 2005 to 19.7% in 2030 [6], and as obesity is 
associated with a large number of medical complications, including cardiovascular disease, 
cancer and metabolic disorders, it poses a major global health issue [4].   
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Diabetes is a metabolic disorder that correlates with obesity and it has been found that 
80% of diabetes cases are directly related to obesity [7], with obesity being the single most 
important predictor for developing diabetes [8]. The increase in obesity prevalence has been 
closely followed by a similarly striking increase in the incidence of diabetes, with more than 
double the number of people suffering from diabetes now compared to 30 years ago. The 
continuous increase in diabetes prevalence has so far exceeded most predictions [4, 5, 9], for 
example in 1995 the prevalence of adults with diabetes was estimated to 135 million and 
predicated to rise to 300 million in 2025 [10], but with an estimated 285 million adults world-wide 
with diabetes in 2010 the prediction has now increased to 439 million adults in 2030. This trend 
indicates that the current pandemic will continue to increase in severity, constituting a growing 
health concern [4]. 
1.1.3 Progression from Obesity to Diabetes 
The pathogenesis of obesity has been studied over the last few decades to understand 
the link between obesity and diabetes, and it is now considered that adipokines secreted from 
adipose tissue hold a key to this link [11]. Accumulation of adipose tissue, especially visceral 
adipose tissue, is associated with insulin resistance, hyperglycemia, dyslipidemia, hypertension 
and pro-inflammatory conditions [12]. Systemic tissue inflammation is induced both by the 
lipotoxicity acting on a variety of tissues causing an intracellular inflammatory response, and 
also through the altered adipokine profile that results from the accumulation of visceral fat tissue 
[13].   
1.2 Adiponectin 
1.2.1 Adipose Tissue: an Endocrine Organ 
Historically adipose tissue and adipocytes were considered to be passive energy storage 
depots, but with the discovery of bioactive adipocyte secreted molecules, termed adipokines, its 
endocrine function has come under increasing investigation and it is now well accepted that 
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adipose tissue functions as an active endocrine organ with many metabolic functions [14]. 
Several adipokines have to date been identified and characterized as playing a role in obesity 
and diabetes including leptin, adiponectin, chemerin, visfatin, omentin, tumor necrosis factor 
alpha (TNFα), resistin, retinol-binding protein 4 (RBP4) and interleukin 6 (IL-6) and vaspin [11, 
14-17].  
1.2.2 Adiponectin Action 
One of the adipocytes secreted from adipose tissue, adiponectin, has been the subject 
of a lot of research over the last two decades and it is now known to act on a number of target 
tissues including, liver, heart, adipose, muscle, endothelium, and the hypothalamus to exert 
several beneficial effects. Adiponectin is generally considered to be anti-diabetic, insulin 
sensitizing, insulin mimetic, cardio-protective, anti-inflammatory and anti-apoptotic [18-20] and 
the interest in studying adiponectin was amplified by the finding that its plasma levels were 
inversely correlated with obesity and diabetes; indeed central fat distribution was an 
independent negative predictor of circulating adiponectin levels suggesting that adiponectin 
might represent a link between obesity and the development of insulin resistance and diabetes 
[21-24].  
1.2.3 Structure and Oligomeric Forms 
Adiponectin was discovered to consist of 247 amino acids; an approximately 30 kDa 
polypeptide with four domains: an N-terminal signal sequence, a variable domain, a collagen-
like domain, and a C-terminal globular domain [25-28]. The gene encoding adiponectin is 
located on chromosome 3q27 [29], a locus that has been linked with susceptibility to diabetes 
and cardiovascular disease [30].  
Plasma concentrations of adiponectin in healthy subjects range between 1.9-17 μg/ml 
[22], with 5-10μg/ml being considered normal levels, making adiponectin highly abundant and 
corresponding to approximately 0.01% of all plasma protein. There are three oligomeric forms of 
3 
adiponectin secreted into the blood stream: low molecular weight (LMW; trimer), medium 
molecular weight (MMW; hexamer), and high molecular weight (HMW; oligomers) [31]. Globular 
adiponectin is a fourth form of adiponectin with biological activity, present in plasma and 
produced by proteolytic cleavage to release the 17 kDa globular domain. Globular adiponectin 
makes up about 1% of total plasma adiponectin [32]. 
1.2.4 Regulation and Assembly 
Assembly and release of adiponectin is regulated by the endoplasmic reticulum (ER). It 
has been shown that pools of folded adiponectin is retained in adipocytes by being bound to the 
ER chaperone ER protein 44 (ERp44), while another ER chaperone, ER oxidoreductin 1p 
(Ero1-Lα), mediates its release from ERp44 and subsequently from the adipocyte [33]. The 
metabolic state of the cell regulates the levels of these ER chaperones which also play an 
important role in the assembly of HMW oligomers of adiponectin [33]. A disulfide-bond 
oxidoreductase-like protein (DsbA-L) has been shown to be a key regulator of adiponectin 
assembly and multimerization, it is highly expressed in adipose tissue with a negative 
correlation with obesity in both mice and human. DsbA-L is stimulated by the insulin sensitizer 
rosiglitazone and inhibited by the inflammatory cytokine TNFα [34].  
The availability of adiponectin is regulated also at the gene expression level and is 
mediated through the transcription factors CCAAT/enhancer binding protein (C/EBP) [35], sterol 
regulatory element-binding protein 1c (SREBP1c) [36], peroxisome proliferator-activated 
receptor gamma (PPARϒ) [37] and sirtuin 1 (SirT1) [38]. After translation the adiponectin 
peptide goes through post-translational modifications such as hydroxylation of proline and lysine 
residues and glycosylation of hydroxylysines which produces multiple isoforms that assemble 
into the LMW, MMW, and HMW adiponectin oligomers secreted into the circulation [39]. 
Secretion of HMW adiponectin complexes is stimulated by SIRT1 via suppression of PPARγ 
causing an upregulation of Ero1-Lα [40] and as the biological function of adiponectin might be 
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dependent on oligomer formation [41], with HMW being the most biologically active form, the 
level of HMW more so than total adiponectin might be important for its anti-diabetic and anti-
inflammatory role [42]. 
1.2.5 Adiponectin Receptors 
The adiponectin receptors AdipoR1 and AdipoR2 identified by Yamaquichi and colleges 
were found to contain seven-transmembrane domains but to be both structurally and 
functionally distinct from guanine nucleotide-binding protein (G-protein) coupled receptors in 
that they do not associate with any G-proteins and have a reverse membrane polarity with a 
cytoplasmic N-terminus and a short extracellular C-terminus [43, 44]. Their importance in 
metabolism was established by a double knock-out study producing mice that presented with 
elevated insulin levels and glucose intolerance. AdipoR1 is mainly expressed in liver, skeletal 
muscle, macrophages and hypothalamus, while AdipoR2 is highly expressed in liver, white 
adipose tissue and vasculature [18].  
1.2.6 Signaling 
The signalling cascade initiated by adiponectin binding to AdipoR1 and AdipoR2 has not 
been completely elucidated and requires further study, but one immediate downstream mediator 
of adiponectin signalling, adaptor protein phosphotyrosine interaction PH domain and leucine 
zipper containing 1 (APPL1), has been identified. Other downstream effects of adiponectin 
regulate glucose and lipid metabolism via activation of adenosine monophosphate-activated 
protein kinase (AMPK) and PPARγ, increasing lipid oxidation and mitochondrial biogenesis 
while decreasing gluconeogenesis. Full adiponectin-mediated AMPK activation is dependent on 
calcium/calmodulin-dependent protein kinase beta (CaMKKβ) and AMP/liver kinase B1 (LKB1) 
[18, 45]. Adiponectin binding to AdipoR stimulates APPL1 association with the receptor which 
leads to an interaction between APPL1 and ras-related protein 5 (Rab5), causing an increased 
glucose transporter type 4 (GLUT4) membrane translocation and glucose uptake in skeletal 
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muscle. This crosstalk between adiponectin and insulin signaling pathways makes APPL1 a 
critical regulator of the insulin mimetic action of adiponectin [46]. 
1.2.7 Functional Significance 
In early loss-of-function studies there was some variability in the report of adiponectin’s 
influence on insulin sensitivity; some studies demonstrated reduced insulin sensitivity [47], some 
reported improvements only in high-fat diet (HFD) fed mice [48] while some did not show any 
effect on insulin signaling at all [49]. However delivery of adiponectin in conditions of obesity 
and diabetes have consistently been shown to stimulate AMPK and PPARγ activity, increasing 
lipid oxidation, reducing free fatty acid (FFA) levels and improving insulin sensitivity and glucose 
tolerance [17, 50, 51] making adiponectin action relevant in the study of obesity and diabetes. 
The strong inverse correlations between adiponectin and both insulin resistance and 
inflammatory states has been well established [52, 53]. Interestingly it has been shown (in non-
human primates) that adiponectin levels decline before obesity and insulin resistance develops, 
suggesting that hypoadiponectinemia might be involved and contribute to the pathogenesis of 
obesity resulting in insulin resistance [54, 55].   
1.2.8 Therapeutic Potential 
Weight-loss and exercise are the initial recommendations to help control blood glucose 
levels in diabetic patients, but if this approach is not enough to manage the disease there are 
several types of medications that can be prescribed to help manage blood glucose levels. 
These, however, are typically associated with adverse effects including weight-gain, digestive 
problems, or even liver damage [56]. Hence identification of new therapeutic targets and their 
specific mechanisms remain relevant research areas.  
The decreased circulating levels of adiponectin in obesity and diabetes together with the 
beneficial effects of adiponectin administration on insulin resistance suggest potential as a 
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diabetes treatment. Indeed it has been shown that one category of diabetes medications, 
thiazolidinediones (TZDs), might partially elicit its beneficial effect via an upregulation of HMW 
adiponectin expression and secretion through PPARγ activation [57-62]. Direct administration of 
adiponectin as a diabetes treatment, however, is not cost-effective as its production requires 
mammalian expression systems and is a time-consuming and labour intensive process. 
Additionally, adiponectin is a protein and would be broken down in the digestive system and 
therefore needs to be administered intravenously which is not an ideal method of delivery. 
Currently there is a lot of interest in finding chemical molecules that can bind and activate 
AdipoR1 and AdipoR2 and mimic adiponectin action in a convenient and cost-effective manner 
[63], and this field of research is expected to accelerate with the recent publication of AdipoR’s 
crystal structure [64].  
1.2.9 Adiponectin and Skeletal Muscle 
Skeletal muscle is one of the most important tissues involved in whole body glucose 
homeostasis, and insulin resistance in skeletal muscle plays a key role in the pathogenesis of 
diabetes making it an important tissue to study in the context of obesity, insulin resistance and 
diabetes [65, 66]. It has recently been shown that in addition to being a receptor of endocrine 
adiponectin action via AdipoR, skeletal muscle express adiponectin, establishing adiponectin as 
a myokine, and the autocrine action of adiponectin has been shown to, at least in part, mediate 
its beneficial anti-diabetic metabolic effects as local production leads to increased glucose 
uptake and improved insulin sensitivity [62, 67]. 
Although the beneficial metabolic effects by adiponectin on skeletal muscle is well 
established, the cellular mechanisms involved have not yet been elucidated [68]; our lab have 
recently published a study that investigated the effect of adiponectin in HFD fed mice on insulin 
sensitivity, which showed that induction of autophagy via AMPK and a reduction of oxidative 
stress was involved in the insulin sensitizing effect of adiponectin [69] but further research is still 
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needed to elucidate the exact mechanism of insulin sensitization by adiponectin in skeletal 
muscle.  
1.3 Skeletal Muscle Insulin Resistance 
1.3.1 Insulin Signaling 
In healthy subjects, elevated glucose levels cause secretion of insulin from the pancreas 
acting on peripheral tissues such as liver, adipose and muscle. Insulin binding to the insulin 
receptor (IR) induces a conformational change resulting in autophosphorylation and activation of 
its intrinsic tyrosine kinase. Activated IR is bound by insulin receptor substrate (IRS) via 
phospho-tyrosine binding (PTB) domains and, upon binding, IR phosphorylate tyrosine residues 
on IRS, allowing it to interact with Scr homology 2 (SH2) domains in the p85 regulatory subunit 
of phosphotidylinositol-3-kinase (PI3K). Interaction with IRS activates the p110 catalytic subunit 
of PI3K which mediate the conversion of phosphatidylinositol 4,5-bisphosphate (PIP2) to 
phosphatidylinositol 3,4,5-triphosphate (PIP3), recruiting and inducing a conformational change 
in AKT allowing its phosphorylation and activation by phosphoinositide-dependent kinase-1 
(PDK-1) on threonine 308 and by mammalian target of rapamycin complex 2 (mTORC2) on 
serine 473. Activated AKT then induces GLUT4 translocation to the plasma membrane via 
Rab5, increasing glucose uptake to the cell [70-73]. Additionally IR activates the mitogen-
activated protein kinase (MAPK) pathways involved in cell growth and differentiation [72]. 
1.3.2 Disruption of Insulin Action in Obesity and Diabetes; JNK 
The ability of IR to phosphorylate IRS-1 on tyrosine residues, required for IRS activation, 
is severely impaired in obese and diabetic subjects compared to healthy, lean subjects. MAPK 
signaling, however, is not affected, suggesting that impairment of insulin signaling occurs at the 
IRS-1 level [74]. It is believed that increased serine phosphorylation of IRS-1 is the cause for the 
impaired tyrosine phosphorylation and, indeed, it has been shown that preventing serine 
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phosphorylation by mutation of serine residues in IRS-1 prevent development of insulin 
resistance in mice on HFD [75].  
The factors responsible for the serine phosphorylation of IRS and the exact mechanism 
by which this happens has not been fully established, but c-Jun N-terminal kinase 1 (JNK1) has 
been suggested as one potential negative regulator of insulin signaling [76]. JNK is activated in 
obesity by inflammatory pathways such as TNFα [76, 77], and knocking out JNK1 has been 
shown to protect against obesity related insulin resistance, placing JNK1 as a link between 
inflammation and metabolic pathways [76, 78].  
1.3.3 Cellular Events Involved in the Development of Insulin Resistance 
In an environment of disrupted cellular homeostasis, such as insulin resistance, a variety 
of cellular responses and signalling cascades are likely to be involved. ER stress and unfolded 
protein response (UPR) signalling as well as autophagy, are important for sensing changes in 
the intracellular milieu, and disruptions in cellular homeostasis can lead to oxidative stress. All of 
these cellular conditions and processes are therefore relevant to study in the context of 
developing insulin resistance and have been implicated in the pathogenesis of obesity and 
diabetes, but their role in skeletal muscle have yet to be fully established [71, 79-84].  
Although it was suggested 30 years ago that skeletal muscle insulin resistance is a main 
contributor to the glucose intolerant state of diabetes, the exact molecular mechanisms that 
leads to development of insulin resistance are still not fully characterized [66, 71]. To be able to 
understand how adiponectin elicits beneficial effects in muscle it is important to understand how 
insulin resistance in muscle develops and which cellular processes are involved. The following 
sections will therefore examine the suggested role of ER stress, UPR signalling, oxidative stress 
and autophagy in skeletal muscle insulin resistance; what is known about the integration 
between these complex cellular events and what is yet to be established.  
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1.4 ER Stress and UPR Signaling  
1.4.1 Endoplasmic Reticulum 
The ER is a cellular organelle responsible for processing of newly synthesized secretory, 
plasma membrane and organelle proteins. It plays an important role in protein synthesis, folding 
and trafficking, calcium homeostasis and lipid synthesis. The ER is a sensor of changes in the 
intracellular milieu, it functions as a communicator between the cytosol and nucleus and induces 
changes in gene expression to maintain cellular homeostasis in response to a variety of stimuli 
[85-88].   
Proteins that require processing in the ER contain a sequence that targets the ribosome 
to the ER, the poly-peptide sequence is then translocated into the ER lumen during translation 
where the signal peptide is cleaved off [89, 90]. The unfolded poly-peptide chain is folded into 
secondary and tertiary structures with the help of a variety of ER chaperones and folding 
enzymes, and the protein structure is stabilized by disulfide bonds and often assembled into 
multimeric complexes, processes that are dependent on the oxidizing environment of the ER 
lumen [85, 90]. Proper folding is sensitive to ER homeostasis which can be disrupted in 
response to a variety of pathophysiological conditions, for example in obesity and diabetes [79, 
91].  
1.4.2 ER Stress and UPR Signaling 
When protein folding and ER function gets compromised it leads to an accumulation of 
unfolded proteins, a condition known as ER stress [86, 92]. ER stress activates the UPR, a 
signaling cascade with downstream targets functioning to alleviate ER stress by increasing the 
folding capacity of the ER, reducing the protein folding load and activating ER associated 
degradation (ERAD) [86, 93].  
This response is mediated through three ER membrane proteins, protein kinase-like ER 
kinase (PERK), inositol-requiring enzyme-1 (IRE1) and activating transcription factor 6 (ATF6) 
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[85-87]. The ER luminal domain of PERK, IRE1 and ATF6 are bound by the ER chaperone 
glucose-regulated protein 78 (GRP78) keeping them inactive, however with an accumulation of 
unfolded proteins GRP78 is titrated away binding to the unfolded proteins, causing activation 
and initiation of PERK, IRE1, ATF6 and their respective downstream signaling cascades. These 
signaling cascades ultimately regulate ER chaperones, folding enzymes, antioxidants, lipid 
synthesis, protein degradation and translational attenuation [87, 88, 94, 95].  
 Dissociation of GRP78 from PERK leads to activation if its serine/threonine kinase 
activity through dimerization and autophosphorylation, pPERK then phosphorylates eukaryotic 
translation initiation factor 2 (eIf2α) which prevents general translation to reduce the protein 
folding load while allowing selective translation of activating transcription factor 4 (ATF4) which 
activates the expression of UPR target genes including chaperones and folding enzymes [94, 
96].  
Activation of IRE1 occurs in the same way as PERK, dissociation of GRP78 from the ER 
luminal domain causing dimerization and autophosphorylation. Phosphorylation of IRE1 
activates its RNase activity cleaving X-box binding protein 1 (XBP1) mRNA allowing translation 
of an active transcription factor that act on a several UPR target genes. Activation of IRE1 also 
leads to phosphorylation and activation of JNK via TNF receptor-associated protein factor 2 
(TRAF2) and apoptosis signal-regulating kinase 1 (ASK1) [94], and additionally pIRE1 degrade 
mRNA to reduce the protein folding load of the ER [86].  
 ATF6 is also activated by dissociation of GRP78, however activation of ATF6 is 
mediated by translocation to Golgi where it is cleaved by site-1 protease (S1P) and site-2 
protease (S2P) to form a 50kDa active transcription factor that translocate to the nucleus to 
active UPR target genes such as chaperones and genes involved in lipid synthesis [86, 97].  
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 Figure 1.1. ER stress and UPR signaling. Disruption of normal Endoplasmic Reticulum (ER) 
function leads to an accumulation of unfolded protein, a condition termed ER stress. 
Increasing ER stress cause an activation of the unfolded protein response (UPR). There are 
three branches of the UPR controlled by three ER transmembrane proteins: PERK, IRE1, and 
ATF6. In normal conditions the ER chaperone GRP78 is bound to their ER luminal domain 
keeping them inactive, however the increased levels of unfolded proteins in ER stress 
conditions cause GRP78 to dissociate allowing their activation (phosphorylation of PERK and 
IRE1 and cleavage of ATF6) and initiation of their respective downstream signaling cascades. 
The function of these signaling cascades is to increase the capacity for protein folding and 
assembly but also to decrease the protein folding load by increasing ER associated 
degradation (ERAD) of unfolded proteins [86, 88, 92, 97]. In addition to ERAD it has been 
suggested that unfolded proteins associated with ER stress are degraded by autophagy with 
the UPR potentially inducing autophagy via activation eIf2α downstream of PERK, but this 
mechanism is yet to be fully established [98-100]. 
Endoplasmic Reticulum (ER); Unfolded Protein Response (UPR); ER associated degradation 
(ERAD). 
 
1.4.3 ER Stress Induced Protein Degradation; Autophagy 
Autophagy has been suggested as one mechanism that alleviates ER stress via 
degradation of unfolded proteins [98, 101] and autophagy deficient models have been shown to 
be more susceptible to developing ER stress and insulin resistance [102, 103]. Autophagy is 
thought be induced in response to ER stress via the UPR and the activation of PERK and eIF2α 
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[98, 101]. Another mechanism via which autophagy is induced in response to ER stress is via 
the IRE1-JNK pathway, which has been shown to be required for autophagy activation after ER 
stress [103]. Additionally XBP1 has been shown to regulate forkhead box protein O1 (FOXO1) 
which is involved in autophagy regulation [104, 105]. However, the exact role of autophagy in 
ER stress needs to be further established. 
1.4.4 ER and ROS Production 
Balance of the sensitive environment in the ER lumen is greatly influenced by redox 
potential, and a close relationship between ER stress and oxidative stress has been 
demonstrated [94] although this relationship is not fully understood as the interaction between 
ER stress, the UPR and oxidative stress is complex. It is known that exposure to oxidative 
stress causes an activation of the UPR [106], that protein folding and disulfide bond formation is 
responsible for 25% of reactive oxygen species (ROS) generation in cells [107], and that 
changes to the redox state of the ER affect its folding capacity leading at an accumulation of 
unfolded proteins and ER stress [85, 94]. Further, ER stress induces release of calcium from the 
ER lumen which triggers production of mitochondrial ROS, and energy depletion (caused by 
energy dependent protein folding) stimulate mitochondrial oxidative phosphorylation to produce 
more adenosine triphosphate (ATP), a process that produces ROS. Several links between 
oxidative stress, ER stress and the UPR has thus been found, but the complex interactions 
between these processes warrant further study, especially in the context of insulin resistance 
and diabetes. 
1.4.5 ER Stress and the UPR in Insulin Resistance and Diabetes 
 A strong correlation between obesity, insulin resistance and diabetes have been well 
established, and one key underlying mechanism has been suggested to be ER stress [82, 108, 
109]. Indeed it has been demonstrated that relieving ER stress through treatment with chemical 
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chaperones or upregulation of the ER chaperone GRP78 lead to restoration of insulin sensitivity 
and glucose tolerance in obese and diabetic mouse models [109-111].  
The link between ER stress and insulin resistance has been shown to involve activation 
of JNK and subsequent phosphorylation of IRS-1 on serine residues, attenuating insulin 
signaling by preventing activating tyrosine phosphorylation of IRS-1 [109, 112]. However, it has 
recently been questioned whether UPR induced JNK activation is directly involved in insulin 
resistance by interfering with insulin signaling, or if these are merely concurrent events [113]. 
Further, although the role of ER stress in obesity related insulin resistance has been well 
established in several tissues such as adipose, pancreas and liver, its involvement in skeletal 
muscle has not yet been established [91] and more research is needed to fully elucidate the role 
of ER stress and the UPR in insulin resistance, especially in skeletal muscle. 
1.5 Oxidative Stress 
1.5.1 ROS Production and Oxidative Stress 
Reactive oxygen species (ROS) is produced as a natural by-product of oxygen in cellular 
events such as enzymatic reactions involving oxidases and energy production in the 
mitochondria [114]. In normal physiological conditions the accumulation of ROS is counteracted 
by the endogenous antioxidant capacity of a cell which involve defenses such as catalase 
reductase, superoxide dismutase (SOD), and redox systems including oxidized 
glutathione/reduced glutathione (GSSG/GSH). In response to cellular stress, however, an 
increase in ROS production can cause an imbalance between ROS production and the 
antioxidant defense, leading to an accumulation of ROS, a condition referred to as oxidative 
stress [94].  
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1.5.2 Oxidative Stress in Diabetes and Insulin Resistance 
Oxidative stress is known to damage cellular constituents such as proteins, lipids and 
nucleic acids and can therefore disrupt organelles and compromise cell viability [115]. Oxidative 
stress is currently being investigated in a number of disease states, including obesity, insulin 
resistance and diabetes [116], and it has been shown that increased levels of ROS together 
with declining cellular antioxidant capacity can lead to the development of insulin resistance, as 
established both by experimental and clinical studies [81, 84, 116, 117].  
Several experimental studies have shown that antioxidant treatments can ameliorate the 
diabetic state [94, 117, 118]. However the failure of clinical trials to mimic this beneficial effects 
[119, 120] points to fact that the role of ROS might be more complex than initially perceived. 
Studies investigating cellular localisation of ROS production and antioxidant response has 
indeed established that ROS and redox signalling plays an important role in normal 
physiological conditions and that production of ROS and oxidative stress are complex and 
compartmentalised events capable of causing molecular modification to regulate a wide variety 
of cellular processes. One cellular process that is suggested to be regulated by ROS is 
autophagy [120, 121].  
   1.5.3 Redox Signaling and Autophagy 
Studies examining the connection between redox signaling and autophagy has so far 
shown that reactive oxygen species are essential for starvation induced autophagy and that 
they directly stimulate the formation of autophagosomes via autophagy related gene-protein 4 
(ATG4) [122, 123]. Production of ROS activates autophagy and, reciprocally, if the autophagic 
machinery is not functioning properly it can lead to the accumulation of ROS. As oxidative stress 
is widely accepted to be involved in insulin resistance and impaired autophagy also has been 
suggested to play a role in developing insulin resistance, the relationship between oxidative 
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stress and autophagy is of relevance to study in the context of insulin resistance and diabetes 
[80, 82, 124].  
1.6 Autophagy 
1.6.1 Autophagy Regulation and Function 
Macroautophagy (hereafter referred to as autophagy) is a cellular bulk degradation 
process in which a double membrane structure is formed around proteins and organelles 
destined for degradation, this membrane elongates and closes around cargo to form an 
autophagosome. The autophagosome then fuses with a lysosome to form an autolysosome, 
undergoes acidification and the proteins and organelles are broken down by proteases and the 
remaining components released back into the cytosol [125]. A complete cycle of autophagy 
resulting in the degradation of cargo is termed autophagic flux [126].  
Autophagy is responsible for degradation and turnover of long-lived proteins and 
organelles allowing major biochemical changes in the cell. Autophagy is upregulated in 
response to external stressors including metabolic changes and hormonal imbalance, and 
internal stressors such as accumulation of proteins aggregates (ER stress) and reactive oxygen 
species (oxidative stress). A constitutive, low level of autophagy is involved in maintenance of 
cellular homeostasis and too much or too little autophagy has been shown to be detrimental; 
properly regulated autophagy is thus important for a variety of cellular needs and in keeping 
cells healthy and viable [127].  
The cytoplasmic regulation of autophagy (Fig. 1.2) has been well studied [128-136], 
however recently it has been suggested that the autophagic response occurs in three phases. 
The cytoplasmic regulation being the first level response, followed by gene regulation as the 
second level response and with epigenetic control and chromatin remodelling being the third 
level response creating an “autophagic memory” having long lasting effects on the process of 
autophagy [137].  
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 Figure 1.2. Cytoplasmic regulation of autophagy. Autophagy involves the formation of a 
double-membrane phagophore structure that form around proteins and organelles targeted 
for degradation. The phagophore membrane elongates and eventually close to form an 
autophagosome. Exercise and low energy/nutrients, as well as adiponectin, are known to 
positively regulate autophagy via AMPK. Activation of AMPK inhibit mTOR complex 1 and 
mediate selective phosphorylation of ULK1 complex on ULK1 S555 which, together with 
Beclin 1, initiate formation of the phagophore membrane [69, 138-141]. Activation of mTOR, 
however, negatively regulates autophagy through phosphorylation of ULK1 S757, and known 
activators of mTOR include insulin, growth factors and high energy/nutrient conditions [128-
131, 142-146]. Two conjugation events are subsequently involved in vesicle elongation. The 
first one include covalent conjugation of ATG12 to ATG5, mediated by ATG7 and ATG10, 
allowing interaction with ATG16. The ATG5/12/16 complex then promote the second 
conjugation event in which pro-LC3 is cleaved by ATG4 where after ATG7 and ATG3 mediate 
conjugation of PE to LC3 forming LC3II [147-149]. LC3II gets incorporated into the 
phagophore membrane and function in cargo recognition as well as phagophore expansion 
[150]. The autophagosome then fuses with a lysosome and goes through acidification to form 
an autolysosome in which the protein and organelle cargo, as well as the inner membrane of 
the autolysosome, are degraded and components released back into the cytosol [125, 151]. 
Going through the complete cycle of this process is termed autophagic flux [126]. 
Autophagy related gene-protein (ATG); unc-51 like autophagy activating kinase 1 (ULK1); 
mammalian target of rapamycin (mTOR); microtubule-associated protein 1A/1B-light chain 3 
(LC3); phosphatidylethanolamine (PE). 
 
1.6.2 The Role of Autophagy in Insulin Resistance and Diabetes 
The role of autophagy in sensing the nutritional state of the cell and responding to 
metabolic stress to maintain cellular homeostasis, together with the observations that autophagy 
is closely connected to ER and oxidative stress regulation and signaling, both well established 
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as playing a role in obesity and diabetes, has resulted in autophagy receiving increasing 
attention in the context of obesity and diabetes, and dysregulation of autophagy have been 
suggested to play a role in the progression of insulin resistance and diabetes in obesity [82].  
It has been shown that in conditions of metabolic stress, beta-cell specific autophagy 
deficiency leads to development of diabetes [82]. Overexpression of ATG5 enhances autophagy 
and leads to increased insulin sensitivity and better tolerance to oxidative damage in mice [152], 
but autophagy knockout in specific insulin target tissues, such as muscle and liver, produced a 
variety of phenotypes [82]. Some demonstrate that autophagy deficiency is involved in 
pathogenesis of insulin resistance and diabetes [153], while some show leanness and 
resistance to diet induced obesity and diabetes [154], highlighting the fact that further studies 
are necessary to elucidate the role of autophagy in obesity, insulin resistance and diabetes.  
1.7 Objectives 
1.7.1 Research Questions and Experimental Model  
Currently available diabetes medications are associated with a variety of side effects and 
novel therapeutic targets, aimed at finding better treatment options with fewer and milder side 
effects, are continually being investigated [56, 155]. Adiponectin has been shown to improve 
metabolic dysfunctions in obesity and diabetes and is currently under investigation as a 
potential diabetes treatment [156, 157]. While skeletal muscle has been identified as an 
important target of adiponectin action [68], the cellular mechanisms involved in the 
pathogenesis of insulin resistance and diabetes, and how these are regulated by adiponectin 
are poorly defined. 
ER stress, UPR signaling, oxidative stress and autophagy are widely accepted to play a 
role in insulin resistance and diabetes [94, 117], however few studies have examined their 
coordinated role in skeletal muscle [91]. As muscle mass makes up 40-50% of the human body, 
and skeletal muscle plays an essential role in metabolism and whole body glucose 
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homeostasis, the cellular processes involved in the pathogenesis of insulin resistance in skeletal 
muscle is of critical relevance to study [158], and further, the interrelationship between these 
cellular processes need to be investigated, especially in the context of skeletal muscle insulin 
resistance. 
Exposure to high insulin and high glucose media (HIHG) for 24hrs has previously been 
shown to induce insulin resistance in L6 skeletal muscle, and extensive evaluation of its effect 
on mediators of insulin signaling and glucose uptake established these conditions as a relevant 
model to examine cellular changes involved in insulin resistance [159] making this model also a 
suitable to examine the mechanisms involved in the insulin sensitizing effect of adiponectin in 
skeletal muscle.  
1.7.2 Study Aims and Hypotheses 
Using this in vitro insulin resistant skeletal muscle model I aim to: Firstly, characterize 
changes in oxidative stress, ER stress, UPR signaling and autophagy in skeletal muscle insulin 
resistance; Secondly, establish the effect of adiponectin on oxidative stress, ER stress, the 
UPR, autophagy and skeletal muscle insulin sensitivity. Thirdly, examine the interrelationship 
between oxidative stress, ER stress, UPR signaling and autophagy in the context of skeletal 
muscle insulin resistance.  
I hypothesise that 1. insulin resistant skeletal muscle cells will exhibit increased levels of 
oxidative stress and ER stress, activation of UPR signaling and impaired autophagy, 2. 
adiponectin will alleviate oxidative stress and ER stress, activate UPR signaling and increase 
autophagy in insulin resistant skeletal muscle, and 3. improving insulin sensitivity and reducing 
ER stress by adiponectin is dependent on autophagy. 
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Chapter 2. Material and Methods 
2.1 Cell Culture 
2.1.1 Culture Conditions 
L6 myoblasts were maintained in alpha-minimum essential medium (AMEM; 5.5mM 
glucose) supplemented with 10% fetal bovine serum (FBS) in 75 cm2 flasks at 37°C in 5% CO2. 
Differentiation from myoblasts (MB) to myotubes (MT) was induced by serum starvation in 2% 
FBS AMEM for 6 days. Prior to treatments, cells were starved for 3 hours in 0.5% FBS AMEM 
with relevant chemical inducers/inhibitors added after 2 hours of starvation allowing a 1 hour 
pre-treatment before inducing insulin resistance. All AMEM contained 5% antibiotic-antimyotic 
solution, and 10% FBS AMEM used for growing stable cell lines contained puromycin to 
continuously select for transgene expressing cells. Culture media and solutions were purchased 
from Wisent Bio Products.  
Cells were incubated in High Insulin (HI; 100nM Humulin R, purchased from Eli Lilly and 
Company) and High Glucose (HG; 25mM D-glucose purchased from Sigma-Aldrich) 0.5% FBS 
AMEM (HIHG) for 24 hours to induce insulin resistance. 
2.1.2 Cell Lines 
L6 GLUT4myc cell line. A stable L6 cell line transfected to overexpress GLUT4 with a myc 
epitope was used to assess insulin stimulated glucose uptake in L6 MB [160].  
GRP78mCherry reporter cell line. A stable L6 GRP78mCherry reporter cell line containing a 
truncated version of the GRP78 promoter controlling the expression of mCherry allowed 
mCherry fluorescence signal to be used a readout of GRP78 gene expression, generally 
accepted as a readout of UPR activation due to its central role in the UPR signaling cascade. 
Inducing ER stress by several well-established pharmacological approaches has been shown to 
cause a marked increase in mCherry red fluorescence [161], although it should be noted that 
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using a fluorescent protein as a readout of gene expression have inherent limitation as there are 
many regulatory steps between gene expression and production of a functional fluorescing 
proteins that could affect the level of fluorescence independent of gene expression regulation, 
such as modifications/alterations that affect translation and protein processing [162, 163] .  
Tandem-fluorescence LC3 cell line. A stable L6 Tandem Fluorescence LC3 cell line (TFLC3) 
containing the gene for LC3 fused to the gene for green fluorescence protein (GFP) and red 
fluorescence protein (RFP) allowed assessment of autophagy in response to selected 
treatments. In this cell line, GFP and RFP co-localize indicating the presence of LC3 by yellow 
fluorescence signal; accumulation of LC3 resulting in ‘puncta’ indicate autophagosomes. As the 
green fluorescence is quenched in the acidic conditions present inside autolysosomes but not 
inside autophagosomes, while the red florescence is preserved also in acidic conditions, the 
red/green fluorescence signal is used as a measurement of autophagic flux indicating 
completion of full cycles of autophagy. 
Atg5K130R mutant cell line. A stable L6 Atg5K130R (Atg5K) dominant negative mutant cell 
line was used as a molecular model of autophagy inhibition. This point mutation prevents 
conjugation to ATG12 and blocks LC3II incorporation and elongation of the autophagosome 
membrane [164-167]. Empty vector (EV) cells were used as control.  
The L6 GLUT4-myc cell line was a kind gift from Dr. Amira Klip (The Hospital for Sick Children, 
Toronto) and GRP78mCherry, TFLC3 and Atg5K130R cells lines were generated by retroviral 
infection as previously described [69]. In short, viral vectors containing the genes of interest 
were transfected into EcoPack 2-293 (Clontech Laboratories, Inc.), a human embryonic kidney-
derived packaging cell line, and the virus-containing culture media was collected 48 hours post-
transfection. After incubation for 24 hours with virus-containing media, L6 cells stably 
overexpressing the transgenes were selected by puromycin antibiotic resistance and maintained 
in puromycin containing growth media. No notable differences in morphology or growth was 
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observed between WT L6 cells and GLUT4-myc, GRP78mCherry, or TFLC3 cell lines. Atg5K 
cells, however, grew slower in comparison EV and WT L6 cells taking an average of 4-6 days to 
reach 100% confluence after seeding, compared to an average of 2-3 days for EV and WT cells. 
Additionally Atg5K MB failed to differentiate into MT and showed no signs of elongation or 
fusion after 8 days in differentiation media (2%FBS AMEM), while EV and WT cells were 
observed as elongated multinucleated MT between day 5-7. This atypical growth and 
differentiation patterns might be attributed to the potential role of autophagy in skeletal muscle 
differentiation and cell cycle regulation [140, 168, 169].   
2.1.3 Reagents 
Adiponectin was dissolved in phosphate buffered saline (PBS) to a stock concentration of 
0.1μg/μl and 50μl/ml was added for a final concentration of 5μg/ml;  
Salubrinal was dissolved in dimethyl sulfoxide (DMSO) to a stock concentration of 3mM and 
10μl/ml was added for a final treatment concentration of 30μM;  
N-acetyl cysteine (NAC) was diluted in PBS to a stock concentration of 500μM and 2μl/ml was 
added for a final concentration of 1mM;  
Tunicamycin was dissolved in DMSO, to a stock concentration of 5mM, and 1.6 µl/ml was 
added for a final treatment concentration of 8µg/ml;  
Rapamycin was dissolved in PBS, to a stock concentration of 27.4µM, and 36.5µl/ml was added 
for a final treatment concentration of 1µM;  
Bafilomycin A1 (Bafilomycin) was dissolved in DMSO, to a stock concentration of 100µM, and 
2µl/ml was added for a final treatment concentration of 200nM.  
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Adiponectin (mouse, mammalian expression system) was purchased from Antibody 
Immunoassay Services (Hong Kong) and all other reagents were purchased from Sigma-
Aldrich. 
2.2 Assays 
2.2.1 Western blotting 
Upon completion of treatment, L6 cells were lysed in denaturing RIPA lysis buffer (50mM 
Tris, 150mM NaCl, 0.1% SDS, 1% Triton X, and 0.5% sodium deoxycholate) containing β-
mercaptoethanol, protease and phosphatase inhibitors, heated for 10 minutes in 90°C, and 
centrifuged at 12000 rpm for 3-15 minutes depending on protein of interest. Samples were 
loaded and ran in 8-15% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE). Proteins were transferred onto a polyvinylidene fluoride (PVDF) membrane at 110V for 
70-85 minutes depending on protein of interest, blocked in 3% bovine serum albumin (BSA) 
blocking buffer, immunoblotted with primary antibodies (pPERK, peIf2α, LC3, pAKT, pmTOR, 
pULK1S757, pAMPK, pULK1S555, β-actin and GAPDH purchased from Cell Signaling, pIRE1 
purchased from Novus Biologicals and ATF6 purchased from Santa Cruz) and subsequently 
with secondary horseradish peroxidase (HRP)-conjugated antibody (anti-rabbit, purchased from 
Cell Signaling). Protein bands were visualized using enhanced chemiluminescence (ECL) 
reagent and developing of exposed film. Band densitometry was determined using Image J, and 
corrected for loading control, β-actin or GAPDH. 
2.2.2 Glucose Uptake 
L6 GLU4myc cells were stimulated with 10 and 100nM insulin for 20 minutes before 
glucose uptake was assessed as previously described [160]. In short, insulin stimulated cells 
were incubated with HEPES-buffered saline solution containing 2-deoxy-D-[3H]glucose, washed 
in saline solution and lysed with NaOH. Cell lysates were put into scintillation vials containing 
3ml of scintillation fluid for radioactivity counting.  
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2.2.3 Thioflavin T – KDEL Immunofluorescence 
Thioflavin T (ThT) dye exhibit increased fluorescence when bound by protein aggregates 
and the levels of fluorescence has been shown to correlate directly with established ER stress 
inducers [93]. ThT dye was added to live cells for 40 minutes (1µM/ml), media was aspirated 
and cells were washed before fixing in 4% paraformaldehyde for 20 minutes. Coverslips were 
mounted on slides in Vectashield mounting media containing DAPI. 
When ThT assay was combined with KDEL immunofluorescence, after fixing, the cells 
were quenched in 0.1% glycine in PBS for 10 minutes, washed with PBS and permeabilized for 
3 minutes in 0.1% Triton X 100. The cells were blocked for 30min in 3% BSA, and then 
incubated overnight at 4°C with 1:500 primary KDEL antibody. After primary incubation the cells 
were washed and subsequently incubated with 1:1000 secondary antibody Alexa Fluor 594 for 1 
hour in the dark at room temperature and washed before coverslips were mounted on slides in 
DAKO mounting media. 
2.2.4 Magic Red 
Magic Red is a cell permeable substrate that fluoresces upon cleavage by cathepsin B 
and increased cathepsin B activity therefore results in more fluorescence signal. Cathepsin B 
targets a wide range of intracellular proteins in lysosomes and Magic Red fluorescence intensity 
can be used as a general measurement of lysosomal activity [170]. After fixing with 4% 
paraformaldehyde for 20 min, the cells were quenched in 0.1% glycine for 10 minutes. Cells 
were permeabilized in 0.1% Triton X 100 for 3 minutes and blocked for 30 minutes in 3% BSA, 
and Magic Red reagent added at 1x concentration according to manufacturer’s protocol and 
incubated for 30 minutes. Cells were washed before coverslips were mounted on slides in 
Vectashield mounting media containing DAPI. 
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2.2.5 Catalase Activity 
Catalase activity was determined using BioVision Catalase Activity Colorimetric Assay 
Kit (#K773-100) according to manufacturer’s instructions. In short, cell lysates were incubated 
with H2O2 (3%, 0.88M) and catalase present in the cell lysates was allowed to convert H2O2 to 
water and oxygen before OxiRed was added. OxiRed reacts with unconverted H2O2 to produce 
as product that can be detected colorimetrically, with catalase activity being reversely 
proportional to the signal detected.  
2.2.6 CellRox Green 
CellRox Green reagent is a cell permeable fluorogenic dye that exhibit bright 
fluorescence when oxidized by reactive oxygen species and was used a measure of oxidative 
stress. Upon completion of treatments, cells were incubated with CellRox Green according to 
the manufacturer’s instructions (#C10444, Molecular Probes Life Technologies) before 
coverslips were mounted on slides in Vectashield mounting media containing DAPI.  
2.3 Analysis 
2.3.1 Fluorescence Confocal Microscopy Imaging 
Microscopy slides prepared from GRP78mCherry and TFLC3 cells lines, as wells as 
slides prepared from ThT-KDEL, MagicRed and CellRox Green assays, were imaged in Zeiss 
LSM 700 Laser Confocal Microscope using solid state lasers; 405nm (blue channel: 405/435 
filter setting), 488nm (green channel: 488/518 filter setting) and 555nm (red channel: 555/585 
filter setting). Gain and offset parameters were optimized for each experiment but kept constant 
between different treatments within an experiment.  
2.3.2 Quantification 
Stacked images (12 slices) were taken for GRP78mCherry experiment and quantified in 
Image J software as average fluorescence intensity per cell for 40 cells/treatment/replicate 
experiment; all other images were taken as single images. TFLC3 experiments were quantified 
25 
as total red/green fluorescence intensity per image for 8-10 images using Zen 2012 Blue 
Edition. ThT–KDEL, CellRox Green and Magic Red were quantified as total green or red 
fluorescence intensity per image divided by the number of cells in the view for 5-10 images 
using Zen 2012 Blue Edition.  
2.3.3 Statistical Analysis 
Comparison between two groups were done using unpaired one-tailed t-test and 
comparisons between multiple groups were done by one-way ANOVA. Significant ANOVAs 
were followed by Tukey’s HSD post hoc test when differences between all groups were of 
interest and Dunnett’s post hoc test when all groups were compared to control. P<0.05 was 
accepted as significant. 
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Chapter 3. Results 
3.1 Characterization of Autophagy, ER stress, the UPR and Oxidative Stress in Skeletal Muscle 
Insulin Resistance 
3.1.1 HIHG Treatment Impaired Insulin Signaling and Insulin Stimulated Glucose Uptake in L6 
Skeletal Muscle Cells 
To validate my insulin resistant model I treated L6 myotubes with HIHG for 24 hours and 
measured the level of AKT phosphorylation in response to 100nM of insulin at 0, 1, 3, 6, 8 and 
10 minutes. In control conditions there was a marked increase in AKT phosphorylation in 
response to insulin stimulation, peaking around 3-6 minutes, while HIHG treated cells showed 
no increase in AKT phosphorylation in response to insulin stimulation (Fig. 3.1A). In line with 
this, 5 minutes of 100nM insulin stimulation resulted in increased glucose uptake for control, but 
not HIHG treated cells (Fig. 3.1B), however 5 minutes of 10nM insulin stimulation did not cause 
an increase in glucose uptake in control or HIHG condition (Fig. 3.1B). The level of AKT 
phosphorylation in response to 5 minutes of 100nM insulin stimulation gradually decreased in 
response to HIHG treatment, measured at 2, 6 and 24 hours, with significantly lower AKT 
phosphorylation for HIHG compared to control condition at each time point (Fig. 3.1C and D). 
These data together demonstrate that HIHG treatment induced insulin resistance in skeletal 
muscle cells.  
27 
 
Figure 3.1. Skeletal muscle insulin resistance was induced by exposing L6 cells to HIHG 
condition. 
(A, C and D) L6 WT MB were differentiated into MT in 6-well cell culture plates in 2% FBS 
AMEM, starved in 0.5% FBS AMEM for three hours and treated with high insulin and high 
glucose media (HIHG; 0.5% FBS AMEM with 100nM insulin and 25mM glucose) for 2, 6 or 24 
hrs. Upon completion of treatments cells were stimulated with 100nM insulin for 0-10 minutes 
(A) and for 5 minutes (C and D), cell lysates were prepared and protein content analyzed by 
western blotting. Representative blots are shown (A and C; n=3) and quantification of band 
densitometry is represented as fold over control (D; n=3) with standard error of mean 
displayed as error bars. 
(B) L6 GLUT4myc MB were grown to 100% confluency in 24-well cell culture plates in 10% 
FBS AMEM, starved in 0.5% FBS AMEM for three hours and treated with HIHG for 24 hours. 
After 5 minutes of 0, 10 or 100nM insulin stimulation (3H)2-deoxy-d-glucose uptake assay was 
performed and represented as fold over control (B; n=3) with standard error of mean 
displayed as error bars.  
AKT phosphorylation in response to 100nM insulin at 0, 1, 3, 6, 8, and 10 minutes in cells 
treated with 24 hrs of HIHG showed more basal phosphorylation of AKT than control 
conditions, but no insulin stimulated increase in pAKT. Although there was some fluctuation in 
AKT phosphorylation over the insulin time course in controls cells, there was a clear increase 
compared to HIHG conditions at each time point (A; n=3). Comparing insulin stimulated AKT 
phosphorylation for 2, 6 and 24 hours of HIHG treatment showed a gradual reduction in HIHG 
treated compared to control cells (C and D; p<0.0001). Glucose uptake was not stimulated by 
10nM of insulin in control or HIHG condition while a significant increase in glucose uptake 
was seen with 100nM insulin stimulation in control but not HIHG condition (B; n=3). 
(B) *Significantly different compared to no-insulin control (P=0.05) 
(D) **/##Significantly different compared to control and 24 hours HIHG treatment. 
^^^Significantly different compared to control, 2 and 6 hours HIHG treatment. (p<0.0001). 
*P < 0.05; **P < 0.01; ***P < 0.001. 
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3.1.2 HIHG Treatment Impaired Autophagosome Formation and Decreased Autophagic Flux 
Next I examined different stages of autophagy using a variety of well-established 
assays. I observed a decrease in the autophagosome marker protein LC3II, concurrent with an 
increase in LC3I, in response to 24 hours of HIHG treatment (Fig. 3.2E and F). TFLC3 
microscopy data further supported a decrease in autophagosome formation as demonstrated by 
the decrease in TFLC3 puncta signifying autophagosomes (Fig. 3.2A). Calculating the red/green 
fluorescence ratio from TFLC3 images confirmed a decrease in autophagic flux in response to 
HIHG treatment (Fig. 3.2A and D) but, contrary to expectation, the decrease in autophagic flux 
in HIHG treated cells was associated with an increase, not decrease, in lysosomal activity as 
determined by MagicRed assay measuring Cathepsin B activity (Fig. 3.2B and C).  
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Figure 3.2. Autophagy was impaired in insulin resistant skeletal muscle cells.  
(A-B and D-E) TFLC3 and WT L6 MB were grown on coverslips to 70% confluency in 12-well 
cell culture plates in 10% FBS AMEM, starved in 0.5% FBS AMEM for three hours before 24 
hours HIHG treatment. TFLC3 L6 MB were fixed upon completion of treatment and MagicRed 
assay was performed on WT L6 MB; 7-9 images per condition were taken by fluorescence 
confocal microscopy. Representative images are shown (A and B; n=6-10); quantification of 
TFLC3 total red/green (D; n=4) and quantification of total MagicRed fluorescence/cell (C; n=3) 
is represented as mean values with standard error of mean displayed as error bars. 
(C and F) L6 WT MB were differentiated into MT in 6-well cell culture plates in 2% FBS 
AMEM, starved in 0.5% FBS AMEM for three hours before the 24 hour HIHG. Upon 
completion of treatments cell lysates were prepared and protein content analyzed by western 
blotting. Representative blots are shown (E; n=7) and quantification of band densitometry is 
represented as fold over control (F; n=7) with standard error of mean displayed as error bars. 
HIHG treatment decreased TFLC3 puncta (A), red/green fluorescence (D; p=0.0133) and 
LC3II (E and F; p=0.0496) compared to control, while lysosomal activity, assessed by Magic 
Red assay, was increased in HIHG condition (B and c; p<0.0001)  
*/** Significant difference compared to control. *P < 0.05; **P < 0.01.  
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Looking closer at the temporal induction of impaired autophagy in response to HIHG 
treatment I found that the decrease in autophagy occurred gradually, measured at 2, 6 and 24 
hours, with a significant decrease in LC3II at 2 and 24 hours but interestingly not at 6 hours, 
while LC3I was unchanged at 2 hours but significantly increased at 6 and 24 hours (Fig. 3.3E, H 
and I). Similarly as for LC3II, there was a gradual decrease in TFLC3 red/green fluorescence 
ratio and therefore autophagic flux, measured at 2, 6 and 24 hours, however autophagic flux 
was significantly different at each time point, both compared to control and compared to the 
other time points (Fig. 3.3A and B). Although there was a marginal increase in LC3II at 6 hours 
compared to 2 hours of HIHG treatment, together these results demonstrated a gradual 
impairment of autophagy in response to HIHG treatment, and I hypothesized that the decrease 
in autophagy was caused by changes in early regulatory events, downregulating 
autophagosome formation, resulting in decreased autophagy. 
Examining early autophagy regulators by western blotting I showed that the autophagy 
inhibitor pmTOR, together with its downstream autophagy specific target, pULK1S757, were 
downregulated compared to control at 2 hours of HIHG treatment but increased at 6 and 24 
hours (Fig. 3.3C-E). pAMPK is known to stimulate autophagy via pULK1S555 but, although 
there was a decrease in both pAMPK and pULK1S555 at 2 hours of HIHG treatment, they 
followed a similar pattern as pmTOR and pULK1S757 with an increase at 6 hours. At 24 hours, 
however, pULK1555 was again downregulated while pmTOR and pULK1S757 were 
upregulated (Fig. 3.3E-G). This regulatory pattern is consistent with the biphasic decrease in 
LC3II, potentially indicating an attempted recovery following the initial impairment in autophagy, 
and these data demonstrate decreased initiation of autophagosome formation in response to 
HIHG treatment at 24 hours. 
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Figure 3.3. Autophagy gradually decreased in response to HIHG treatment.  
(A and B) TFLC3 L6 MB were grown on coverslips to 70% confluency in 12-well cell culture 
plates in 10% FBS AMEM, starved in 0.5% FBS AMEM for three hours before 2, 6, or 24 
hours of HIHG treatment. TFLC3 L6 MB were fixed and mounted upon completion of 
treatment and 5-9 images per condition was taken by fluorescence confocal microscopy. 
Representative images are shown (A; n=3) and quantification of TFLC3 total red/green 
fluorescence is represented as fold over control (B; n=3) with standard error of mean 
displayed as error bars. 
(C-G and H-I) L6 WT MB were differentiated into MT in 6-well cell culture plates in 2% FBS 
AMEM, starved in 0.5% FBS AMEM for three hours before 2, 6, or 24 hour HIHG treatment. 
Upon completion of treatments cells were stimulated with 100nM of insulin for 5 minutes, cell 
lysates were subsequently prepared and protein content analyzed by western blotting. 
Representative blots are shown (E) and quantification of band densitometry is represented as 
fold over control (C-D and F-I; n=3) with standard error of mean displayed as error bars. 
pmTOR and pULK1 S757 were decreased at 2 hours but increased at 6 and 24 hours (E, C; 
p=0.0090 and D; p=0.0258). pAMPK and pULKS555 were similarly decreased at 2 hours but 
increased at 6 hours, however at 24 hours there was no difference compared to control in 
pAMPK, while pULK1 S555 was decreased (E and F; p=0.0278, G; p=0.0181). LC3II showed 
a gradual decrease at 2, 6 and 24 hours compared to control with significant difference at 2 
and 24 hours (E and I; p=0.0114), and a corresponding increase in LC3I for HIHG compared 
to control at 6 and 24 hours (E and H; p=0.0004). There was a gradual decrease in TFLC3 
red/green fluorescence in response to HIHG treatment with significant differences at 2, 6 and 
24 hours (A and B; p<0.0001). 
(B) ***/###/^^^ Significant difference between all conditions. p<0.0001 
(C) *Significant difference compared to 6 and 24 hrs. #Significant difference compared to 
control and 2 hrs. ^Significant difference compared to 2 hrs. p=0.0100 
(D) *Significant difference compared to 6 and 24 hrs. #Significant difference compared to 2 
hrs. ^Significant difference compared to 2 hrs. p=0.0206 
(F) *Significant difference compared to 2hrs. #Significant difference compared to 6 hrs. 
p=0.0278 
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(G) *Significant difference compared to 6 hrs. #Significant difference compared to 2 hrs. 
^Significant difference compared to 6 hrs. p=0.0181 
(H) *Significant difference compared to 6 hrs. #Significant difference compared to control and 
2 hrs. p=0.0148 
(I) *Significant difference compared to control. ^^Significant difference compared to control. 
p=0.0097 
*P < 0.05; **P < 0.01; ***P < 0.001.  
 
3.1.3 HIHG Treatment Increased ER Stress and UPR Activation 
 To examine whether the impairment in autophagy, caused by HIHG treatment, was 
associated with an increase in ER stress, I performed ThT assay directly assessing the level of 
unfolded proteins, the hallmark of ER stress, which showed an increase of unfolded proteins 
compared to control after 24 hours of HIHG treatment (Fig. 3.4A and B). The increase in ER 
stress was, as expected, accompanied by an increase in UPR activation, determined by a 
GRP78mCherry reporter assay in which mCherry red fluorescence was used a general readout 
of UPR activation (Fig. 3.4C and D). Looking in detail at the UPR response, examining 
activation of the individual branches involved, namely IRE1, PERK and ATF6, I showed that 
their activation was increased in response to 24 hours of HIHG treatment (Fig. 3.5A-D), while 
the downstream target of pPERK, peIf2α, was downregulated (Fig. 3.5A and E).    
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Figure 3.4. ER stress and UPR activation was increased in insulin resistance skeletal muscle 
cells.  
(A-D) GRP78mCherry and WT L6 MB were grown on coverslips to 70% confluency in 6-well 
cell culture plates in 10% FBS AMEM, starved in 0.5% FBS AMEM for three hours before 24 
hours HIHG treatment. GRP78mCherry L6 MB were fixed and mounted upon completion of 
treatment and ThT assay was performed on WT L6 MB, then fixed and mounted in DAPI; 9-
12 images per condition was taken by fluorescence confocal microscopy and representative 
images are shown (A and C; n=3-7). Quantification of total ThT green fluorescence/cell and 
mean mCherry fluorescence/cell are represented as mean values (B and D; n=3-7) with 
standard error of mean displayed as error bars. 
HIHG increased ThT fluorescence, and thus the level of unfolded proteins, compared to 
control (A and B; p=0.0178) correlating with increased UPR activation as measured by red 
fluorescence using GRP78mCherry reporter cells (C and D; p=0.0007). Tunicamycin is a 
known ER stress inducer used as a positive control also showing increased ThT and 
GRP78mCherry induction (A and C). 
*/*** Significantly different compared to control. 
*P < 0.05; **P < 0.01; ***P < 0.001. 
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Figure 3.5. All three branches of the UPR were activated in insulin resistant skeletal muscle 
cells.  
L6 WT MB were differentiated into MT in 6-well cell culture plates in 2% FBS AMEM, starved 
in 0.5% FBS AMEM for three hours before 24 hours HIHG treatment. Upon completion of 
treatments cell lysates were prepared and protein content analyzed by western blotting. 
Representative blots are shown (A; n=4-7) and quantification of band densitometry is 
represented as fold over control (B-E; n=4-7) with standard error of mean displayed as error 
bars. 
All there mediators of the UPR response were upregulated in response to HIHG treatment (A, 
B; p=0.013, C; p<0.0001, D; p=0.0454), peIf2α however was decreased despite being directly 
downstream of pPERK (E; p=0.0134).  
*/***Significantly different compared to control. *P < 0.05; **P < 0.01; ***P < 0.001.  
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 To confirm that the unfolded proteins detected using ThT assay were indeed 
localized to the ER, I performed a co-localization assay with ThT and KDEL 
immunofluorescence (Fig. 3.6). KDEL is an ER retention sequence present in most ER 
chaperones and foldases, a well-established marker of the ER, and merged imaged of ThT and 
KDEL fluorescence demonstrated that increased ThT green fluorescence correlated with 
increased yellow fluorescence caused by co-localization with KDEL red fluorescence (Fig. 3.6A 
and D). Using Manders co-localization coefficient (M1) I confirmed that the observed ThT green 
fluorescence signal almost exclusively localized to areas with red fluorescence (Fig. 3.6E; 
M1=0.99) demonstrating that the increase in unfolded proteins was ER specific, and indeed 
signified ER stress. Further supporting an increase in UPR activation there was also an 
increase in KDEL after 24 hours of HIHG treatment but examining ER stress and UPR activation 
at 4 hours showed no increase in KDEL or ER stress (Fig. 3.6A, C and D), demonstrating that 
ER stress and UPR activation in response to HIHG treatment increased later, between 4 and 24 
hours. Examining the individual branches of the UPR confirmed that also ATF6 and pPERK 
activation in response to HIHG was apparent only at 24 hours (Fig. 3.6B) however, interestingly, 
pIRE1 activation was increased in response to HIHG treatment at 2, 6 and 24 hours (Fig. 3.6B), 
and peIf2α showed an initial increase after 2 hours, no difference compared to control after 6 
hours and a decrease after 24 hours of HIHG treatment (Fig. 3.6B). 
 
36 
 
Figure 3.6. ER stress is increased in response to 24 but not 4 hours of HIHG treatment.  
(A and C-E) L6 MB were grown on coverslips to 70% confluency in 12-well cell culture plates 
in 10% FBS AMEM, starved in 0.5% FBS AMEM for three hours before the 4 or 24 hours 
HIHG treatment. ThT-KDEL co-immunofluorescence assay was performed and 5-9 images 
per condition was taken by fluorescence confocal microscopy. Representative images of 24 
hours HIHG treatment are shown (A) and quantification of total fluorescence/cells is 
represented as fold over control (C and D; n=4) with standard error of mean displayed as 
error bars. 
(B) L6 WT MB were differentiated into MT in 6-well cell culture plates in 2% FBS AMEM, 
starved in 0.5% FBS AMEM for three hours before 2, 6 and 24 hours HIHG treatment. Upon 
completion of treatments cell lysates were prepared and protein content analyzed by western 
blotting. Representative blots are shown (B; n=3). 
ThT assay showed increased levels of unfolded proteins at 24 but not 4 hours of HIHG 
treatment (A, D; p=0.0024) and KDEL was similarly increased at 24 but not 4 hours in 
response to HIHG treatment (C; p=0.002). Manders Coefficient analysis of co-localization of 
ThT to KDEL fluorescence (M1) showed that the increase in unfolded proteins was ER 
specific (E; M1=0.99 for 24 hours and 0.92 for 4 hours). Assessment of UPR signaling 
proteins in response to 2, 6 and 24 hours of HIHG treatment showed that pIRE1 is gradually 
increased at 2, 6 and 24 hours while ATF6 and pPERK were increased only at 24 hours (B). 
peIf2α increased at 2 hours, showed no difference at 6 hours, and decreased at 24 hours in 
HIHG compared to control condition (B). 
*P < 0.05. 
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3.1.4 HIHG Increased Oxidative Stress 
 I investigated whether oxidative stress was induced in response to HIHG treatment, and 
using CellRox Green for detection of intracellular ROS, I showed that there was an increase in 
ROS accumulation in response to 24 hours of HIHG treatment (Fig. 3.7A and B). Interestingly, 
catalase activity was also increased (Fig. 3.7C), however the inability of the increased 
antioxidant response to mitigate ROS production, leading to ROS accumulation, support that 
HIHG treatment increased oxidative stress.  
 
 
Figure 3.7. Oxidative stress was increased in insulin resistant skeletal muscle cells.  
(A-B) WT L6 MB were grown on coverslips to 70% confluency in 6-well cell culture plates in 
10% FBS AMEM, starved in 0.5% FBS AMEM for three hours before the 24 hours HIHG 
treatment. Upon completion of treatment CellRox Green assay was performed and 9-12 
images per condition was taken by fluorescence confocal microscopy. Representative images 
are shown (A; n=3) and quantification of total green fluorescence/cell is represented as mean 
fold over control (B; n=3) with standard error of mean displayed as error bars. 
(C) L6 WT MB were grown in in 96-well cell culture plates in 10% FBS AMEM, starved in 
0.5% FBS AMEM for three hours before the 24 hours HIHG treatment. Upon completion of 
treatment catalase activity was determined and represented as mean fold over control (C; 
n=3) with standard error of mean displayed as error bars.  
HIHG increased ROS (A and B; p=0.0464) and catalase activity (C; p=0.0106) compared to 
control.  
*Significantly different compared to control. *P<0.05. 
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3.2 Investigating the Insulin Sensitizing Action of Adiponectin in Skeletal Muscle Insulin 
Resistance 
To examine the effect of adiponectin in skeletal muscle insulin resistance I treated L6 cells 
with adiponectin in control and HIHG condition and assessed changes in insulin signaling, 
autophagy, ER stress and the UPR response. 
3.2.1 Adiponectin Restored Autophagy and Improved Insulin Sensitivity in HIHG Treated Cells 
 I first confirmed the insulin sensitizing effect of adiponectin by looking at AKT 
phosphorylation in HIHG condition with or without adiponectin treatment, demonstrating an 
increase in insulin stimulated AKT phosphorylation with adiponectin compared to HIHG 
treatment alone (Fig. 3.8F and E). I further showed that adiponectin directly restored the 
impaired autophagy seen in response to HIHG treatment, supported by increased LC3II protein, 
TFLC3 puncta and red/green fluorescence with adiponectin treatment in HIHG condition (Fig. 
3.8A, B, C and D). 
 
 
39 
 
Figure 3.8. Adiponectin increased AKT phosphorylation and autophagy in insulin resistant 
skeletal muscle cells.  
(A-B) TFLC3 L6 MB were grown on coverslips to 70% confluency in 12-well cell culture plates 
in 10% FBS AMEM, starved in 0.5% FBS AMEM for three hours before 24 hours HIHG 
treatment + one hour adiponectin pre-treatment. TFLC3 L6 MB were fixed upon completion of 
treatment and 5-9 images per condition were taken by fluorescence confocal microscopy. 
Representative images are shown (A; n=4) and quantification of TFLC3 total red/green 
fluorescence is represented as mean values (C; n=4) with standard error of mean displayed 
as error bars. 
(C-F) L6 WT MB were differentiated into MT in 6-well cell culture plates in 2% FBS AMEM, 
starved in 0.5% FBS AMEM for three hours before 24 hours HIHG treatment + one hour 
adiponectin pre-treatment. Upon completion of treatments, cells were stimulated with 100nM 
of insulin for 5 minutes to examine pAKT, cell lysates were subsequently prepared and 
protein content analyzed by western blotting. Representative blots are shown (C and F) and 
quantification of band densitometry is represented as fold over control (D and E; n=3-4) with 
standard error of mean displayed as error bars. 
Adiponectin treatment increased TFLC3 puncta (A), red/green fluorescence (B; p=0.0001) 
and LC3II (C and D; p=0.0172) in HIHG condition. Further, adiponectin also increased insulin 
stimulated AKT phosphorylation (E; p=0.0043 and F) in HIHG condition.  
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3.2.2 Adiponectin did not Increase Autophagy or Improve Insulin Sensitivity in HIHG Treated EV 
or Atg5K Cells  
 To examine if restoring autophagy was imperative for improving insulin sensitivity I 
compared insulin stimulated AKT phosphorylation in autophagy deficient Atg5K cells to empty 
vector control (EV) cells in HIHG condition with or without adiponectin treatment. There was a 
decrease in pAKT in Atg5K compared to EV in control condition, with a further decrease caused 
by HIHG treatment in both EV and Atg5K cells, but no significant increase in response to 
adiponectin treatment in EV or Atg5K cells (Fig. 3.9A and D). Interestingly, however, HIHG 
treatment of EV cells increased LC3II, in direct contrast with the response observed in wild type 
(WT) cells, and adiponectin was unable to significantly increase LC3II further in HIHG conditions 
in EV cells (Fig. 3.9C and F). There was however an increasing trend for both LC3II and pAKT 
in response to adiponectin in HIHG condition in EV cells. HIHG treatment in Atg5K cells 
increased pmTOR which was reduced to control levels by adiponectin treatment (Fig. 3.9B and 
E), and as expected, LC3II was decreased in Atg5K compared to EV cells in both control and 
HIHG conditions (Fig. 3.9C and F).  
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Figure 3.9 Analysis of autophagy and insulin signaling in EV and Atg5K cells and regulation 
by adiponectin.  
L6 EV and Atg5K MB were grown to 100% confluence in 6-well cell culture plates in 10% FBS 
AMEM, starved in 0.5% FBS AMEM for three hours before 24 hours HIHG treatment + one 
hour adiponectin pre-treatment. Upon completion of treatments, cell lysates were prepared 
and protein content analyzed by western blotting. Representative blots are shown (A-C) and 
quantification of band densitometry is represented as fold over control (D-F; n=2) with 
standard error of mean displayed as error bars. 
There was a decrease in pAKT in Atg5K compared to EV cells, HIHG treatment reduced 
pAKT in both EV and Atg5K cells and no increase was seen with adiponectin treatment in 
either cell type (A and D; p<0.0001). HIHG treatment in Atg5K cells increased pmTOR, which 
was decreased by adiponectin treatment (B and E; p=0.0020). LC3II levels were decreased in 
Atg5K compared to EV cells both in control and HIHG conditions, and HIHG increased LC3II 
in EV but not Atg5K cells (C and F; p=0.033).  
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3.2.3 Adiponectin Alleviated ER Stress in WT and EV but not Atg5K Cells 
 Next I examined the effect of adiponectin on ER stress and demonstrated that 
adiponectin decreased ER stress in HIHG condition as measured by ThT green fluorescence 
(Fig. 3.10A and C) and increased UPR activation in both control and HIHG condition, as 
measured by GRP78mCherry red fluorescence (Fig. 3.10B). Activation of pIRE1 and pPERK 
was unchanged in both control and HIHG conditions (Fig. 3.10F, D and H), while ATF6 was 
decreased in HIHG conditions in response to adiponectin treatment (Fig. 10F and G). Further, 
adiponectin treatment resulted in a decreased trend in control conditions and an increased trend 
in HIHG conditions of peIf2α levels (Fig. 10F and E). 
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Figure 3.10. Adiponectin stimulated UPR activation and alleviated ER stress in insulin 
resistant skeletal muscle cells.  
(A-C) GRP78mCherry and WT L6 MB were grown on coverslips to 70% confluency in 12-well 
cell culture plates in 10% FBS AMEM, starved in 0.5% FBS AMEM for three hours before the 
24 hours HIHG treatment + one hour adiponectin pre-treatment. GRP78mCherry L6 MB were 
fixed upon completion of treatment and ThT assay was performed on WT L6 MB; 5-9 images 
per condition was taken by fluorescence confocal microscopy. Representative images are 
shown (A and B; n=3) and quantification of ThT green fluorescence/cell is represented as 
mean values (C; n=3) with standard error of mean displayed as error bars. 
(D-H) L6 WT MB were differentiated into MT in 6-well cell culture plates in 2% FBS AMEM, 
starved in 0.5% FBS AMEM for three hours before the 24 hours HIHG treatment + one hour 
adiponectin pre-treatment. Upon completion of treatments, cell lysates were prepared and 
protein content analyzed by western blotting. Representative blots are shown (F) and 
quantification of band densitometry is represented as fold over control (D, E, G and H; n=4-5) 
with standard error of mean displayed as error bars.  
Adiponectin decreased ThT green fluorescence in HIHG condition (A and C; p=0.0001) and 
increased GRP78mCherry red fluorescence in both control and HIHG condition (B). 
Adiponectin pre-treatment did not change pIRE1 (F and D; p=0.0021) or pPERK (F and H; 
p=0.0005, but reduced ATF6 (F and G; p=0.0454H) and increased peIf2α in HIHG condition 
(F and E; p=0.0397). *P < 0.05; **P < 0.01. 
(C) **Significant difference compared to Con, Ad and Ad+HIHG. (p=0.0001) 
(D) **/#Significant difference compared to Con and Ad+HIHG treatment. (p=0.0021) 
(E) *Significant difference compared to Con, Ad and Ad+HIHG. (p=0.0397) 
(G) *Significant difference compared to Con. (p=0.0454) 
(H) **/#Significant difference compared to Con and Ad. (p=0.0325) 
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 To test if the increase in autophagy, stimulated by adiponectin in HIHG condition, 
mediated the adiponectin mediated reduction in ER stress I assessed the ability of adiponectin 
to alleviate ER stress in Atg5K cells compared to EV cells (Fig. 3.11). Adiponectin reduced ER 
stress in both control and HIHG conditions in EV cells, but not in Atg5K cells (Fig. 3.11A, B, D 
and E), however there was a decreased trend in ER stress in response to adiponectin treatment 
in both control and HIHG condition also in Atg5K cells (p=0.1044).  
Further I examined the regulation of UPR signaling proteins in EV and Atg5K cells; in EV 
cells HIHG treatment caused an increase in ATF6, demonstrating similar levels of ATF6 as was 
seen for Atg5K cells in control conditions but there was no further increase in ATF6 in Atg5K 
cells with HIHG treatment (Fig. 3.11C and F). Although there was no significant change in 
pPERK in Atg5K or EV cells with HIHG or adiponectin treatment (Fig. 3.11C and G), peIf2α was 
increased in Atg5K cells compared to EV cells and by HIHG treatment in both EV and Atg5K 
cells but there was no change with adiponectin treatment (Fig. 3.11C and H).  
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Figure 3.11. ER stress is alleviated by adiponectin in EV but not Atg5K cells.  
(A-B and D-E) L6 EV and Atg5K MB were grown on coverslips to 70% confluency in 12-well 
cell culture plates in 10% FBS AMEM, starved in 0.5% FBS AMEM for three hours before the 
24 hours HIHG treatment + one hour adiponectin pre-treatment. ThT assay was performed 
and 5-9 images per condition was taken by fluorescence confocal microscopy. 
Representative images are shown (A) and quantification of total fluorescence/cells is 
represented as fold over control (B and C; n=3) with standard error of mean displayed as 
error bars.  
(C, F-H) L6 EV and Atg5K MB were grown to 100% confluence in 6-well cell culture plates in 
10% FBS AMEM, starved in 0.5% FBS AMEM for three hours before the 24 hours HIHG 
treatment + one hour adiponectin pre-treatment. Upon completion of treatments, cell lysates 
were prepared and protein content analyzed by western blotting. Representative blots are 
shown (C) and quantification of band densitometry is represented as fold over control (F-H; 
n=2) with standard error of mean displayed as error bars.  
Adiponectin decreased ER stress in EV (A and B; p=0.0011) but not in Atg5K cells (D and E; 
p=0.1044). There is no difference in ATF6 and pPERK for any treatments in EV or Atg5K cells 
(C, F; p=0.4686 and G; p=0.7023), but pairwise comparison indicate that HIHG increased 
ATF6 in EV cells (C and F; p=0.0192). HIHG increased peIf2α in both EV and Atg5K cells, but 
there was no change with adiponectin treatment (C and H; p=0.0005). *P < 0.05; **P < 0.01. 
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3.3 Examining the Relationship between Autophagy, ER Stress, UPR Signaling, Oxidative 
Stress and Skeletal Muscle Insulin Resistance 
3.3.1 Blocking Autophagy with Bafilomycin Caused ER Stress and Insulin Resistance 
To further examine the influence of autophagy on cellular processes implicated in insulin 
resistance I treated L6 cells with bafilomycin, a known autophagy inhibitor. I first confirmed that 
bafilomycin treatment inhibited autophagy, and although there was an increase in LC3II in 
response to bafilomycin (Fig. 3.12D and E), this increase corresponded to an accumulation of 
autophagosomes (Fig. 3.12A), and assessing TFLC3 red/green fluorescence demonstrated that 
autophagic flux was decreased in response to bafilomycin treatment (Fig. 3.12A and C). 
Further, decreased autophagic flux was accompanied with increased lysosomal activity (Fig. 
3.12B).  
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Figure 3.12. Bafilomycin treatment decreased autophagy.  
(A-C) TFLC3 and WT L6 MB were grown on coverslips to 70% confluency in 12-well cell 
culture plates in 10% FBS AMEM, starved in 0.5% FBS AMEM for three hours before 24 
hours HIHG treatment + one hour bafilomycin pre-treatment. TFLC3 L6 MB were fixed upon 
completion of treatment and MagicRed assay was performed on WT L6 MB; 5-9 images per 
condition was taken by fluorescence confocal microscopy. Representative images are shown 
(A and B; n=3-4) and quantification of TFLC3 total red/green fluorescence is represented as 
mean values (C; n=4) with standard error of mean displayed as error bars. 
(D and E) L6 WT MB were differentiated into MT in 6-well cell culture plates in 2% FBS 
AMEM, starved in 0.5% FBS AMEM for three hours before the 24 hours HIHG treatment + 
one hour bafilomycin pre-treatment. Upon completion of treatments, cell lysates were 
prepared and protein content analyzed by western blotting. Representative blots are shown 
(D) and quantification of band densitometry is represented as fold over control (E; n=4) with 
standard error of mean displayed as error bars. 
Bafilomycin treatment decreased TFLC3 red/green fluorescence in both control and HIHG 
conditions (A and C, p=0.0043) but increased TFLC3 puncta accumulation (A) and LC3II (D 
and E, p=0.0125). Lysosomal activity increased in response to bafilomycin treatment (B).  
(C) **/#/^ Significant difference compared to control.  
(E) * Significant difference compared to control, Baf and Baf+HIHG treatment. #/^ Significant 
difference compared to control and HIHG. *P < 0.05; **P < 0.01. 
For uncut blots see Appendix A, Supplementary Figure 1.  
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I then looked at the functional significance of impaired autophagy in the context of insulin 
resistance and its regulation of cellular processes involved. I demonstrated that bafilomycin 
treatment was associated with increased ER stress (Fig. 3.13A and C), and further that 
bafilomycin caused a decrease in insulin stimulated AKT phosphorylation (Fig. 3.13B and E).  
 
 
Figure 3.13. Inhibiting autophagy with bafilomycin treatment increased ER stress and 
decreased AKT phosphorylation.  
(A, C and D) L6 MB were grown on coverslips to 70% confluency in 12-well cell culture plates 
in 10% FBS AMEM, starved in 0.5% FBS AMEM for three hours before 24 hours HIHG 
treatment + one hour bafilomycin pre-treatment. ThT-KDEL co-immunofluorescence assay 
was performed and 5-9 images per condition was taken by fluorescence confocal microscopy. 
Representative images of ThT are shown (A) and quantification of total fluorescence/cells is 
represented as fold over control (C and D; n=4) with standard error of mean displayed as 
error bars. 
(B and E) L6 WT MB were differentiated into MT in 6-well cell culture plates in 2% FBS 
AMEM, starved in 0.5% FBS AMEM for three hours before the 24 hours HIHG treatment + 
one hour bafilomycin pre-treatment. Upon completion of treatments cells were stimulated with 
100nM of insulin for 5 minutes, cell lysates were subsequently prepared and protein content 
analyzed by western blotting. Representative blots are shown (B) and quantification of band 
densitometry is represented as fold over control (E; n=4) with standard error of mean 
displayed as error bars. 
Bafilomycin treatment increased ER stress (A and C; p=0.0208). KDEL immunofluorescence 
however did not show any difference with bafilomycin treatment (D; p=0.1391). Bafilomycin 
decreased AKT phosphorylation in both control and HIHG conditions (B and E; p<0.0001).  
(C) *Significant difference compared to control. #Significant difference compared to control 
and HIHG treatment.  
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(E) *Significant difference compared to control. #Significant difference compared to control, 
HIHG and Baf+HIHG treatment. ^Significant difference compared to control and Baf 
treatment. *P < 0.05; **P < 0.01. 
For uncut blots see Appendix A, Supplementary Figure 1. 
 
 
3.3.2 Rapamycin Treatment Reduced ER Stress in EV but not in Atg5K Cells 
After establishing that bafilomycin caused ER stress and insulin resistance, I wanted to 
determine whether inducing autophagy by rapamycin, a known pmTOR inhibitor and autophagy 
stimulator, could alleviate ER stress and insulin resistance induced by HIHG treatment. I first 
confirmed that rapamycin treatment induced autophagy, demonstrated by the increased TFLC3 
red/green fluorescence ratio in response to rapamycin in control condition and further that 
rapamycin treatment restored autophagy in HIHG treated cells (Fig. 3.14A and B). Rapamycin 
also alleviated ER stress in EV cells treated with HIHG (Fig. 3.14C and E), however in Atg5K 
cells there was no significant reduction in ER stress in HIHG condition by rapamycin treatment 
(Fig. 3.14D and F). 
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Figure 3.14. Rapamycin treatment increased autophagic flux and decreased HIHG induced 
ER stress in EV but not Atg5K cells.  
TFLC3, EV and Atg5K L6 MB were grown on coverslips to 70% confluency in 12-well cell 
culture plates in 10% FBS AMEM, starved in 0.5% FBS AMEM for three hours before 24 
hours HIHG treatment + one hour rapamycin pre-treatment. TFLC3 L6 MB were fixed upon 
completion of treatment and ThT assay was performed on EV and Atg5K L6 MB; 5-9 images 
per condition was taken by fluorescence confocal microscopy. Representative images are 
shown (A, C and D) and quantification of total fluorescence/cells is represented as fold over 
control (B, E and F; n=4) with standard error of mean displayed as error bars. 
Rapamycin stimulated autophagic flux in both control and HIHG conditions (A and B; 
p<0.0001). ER stress was reduced by rapamycin in HIHG condition in EV cells (C and E; 
p=0.0177) but not in Atg5K cells (D and F; p=0.6669).  
(B) *Significant difference compared to control and Rap treatments. ###Significant difference 
compared to control, HIHG, Rap+HIHG. ^^^Significant difference compared to control and 
Rap treatments.  
(E) *Significant difference compared to control, Rap and Rap+HIHG. *P < 0.05; **P < 0.0; ***P 
< 0.001.  
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To examine the effect of rapamycin treatment on proteins involved in autophagy, insulin 
signaling and the UPR response in HIHG condition, and to confirm that responses were caused 
by the autophagy stimulating effect of rapamycin, I examined protein expression in HIHG 
condition in EV and Atg5k cells, with or without rapamycin treatment. These results surprisingly 
showed that rapamycin reduced pmTOR phosphorylation in Atg5K but not EV cells (Fig. 3.15A 
and B) and similarly that rapamycin increased AKT phosphorylation in Atg5K but not in EV cells 
(Fig. 3.15A and D). Although there was an increased trend in LC3II in EV cells with rapamycin 
treatment, this increase was not significant (Fig. 3.15A and C). I also examined pPERK and 
peIf2α which were decreased by rapamycin treatment in Atg5K cells (Fig. 3.15A, F and G), 
there was also a decreased trend in ATG6, although this reduction was not significant (Fig. 
3.15A and E). These proteins were not altered in EV cells by rapamycin treatment in HIHG 
condition (Fig. 3.15A, E, F and G). 
 
 
 
52 
 
Figure 3.15. Regulation of proteins involved in the UPR response, insulin signaling and 
autophagy by rapamycin in EV and Atg5K cells.  
L6 EV and Atg5K MB were grown to 100% confluence in 6-well cell culture plates in 10% FBS 
AMEM, starved in 0.5% FBS AMEM for three hours before 24 hours HIHG treatment + one 
hour rapamycin pre-treatment. Upon completion of treatments, cell lysates were prepared and 
protein content analyzed by western blotting. Representative blots are shown (A) and 
quantification of band densitometry is represented as fold over control (B-G; n=2) with 
standard error of mean displayed as error bars.  
Rapamycin reduced pmTOR in Atg5K but not EV cells (B; p=0.0057) however no significant 
increase in LC3II was seen in response to rapamycin treatment in either EV or Atg5K cells, 
although LC3II showed an increased trend in EV cells (C; p=0.0616). In Atg5K cells there is 
less pAKT than in EV cells in HIHG conditions, and in EV cells rapamycin treatment lowered 
pAKT but increased it in Atg5K cells (D; p=0.0288). Rapamycin did not change the levels of 
ATF6 (E; p=0.4710) or pPERK (F; p=0.1580), although individual analysis of each cell type 
suggest that rapamycin decreased pPERK in Atg5K cells (F; p=0.0082) and similarly 
rapamycin decreased peIf2α in Atg5K cells (G; p=0.0339). *P < 0.05; **P < 0.01. 
For uncut blots see Appendix A, Supplementary Figure 2. 
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3.3.3 Salubrinal Treatment Reduced ER Stress and Increased Autophagy  
 Salubrinal is a known inhibitor of ER stress and specifically inhibits dephosphorylation of 
peIf2α leading to increased levels of peIf2α keeping the UPR response active. As expected, 
peIf2α was increased in response to salubrinal treatment in HIHG condition, however there was 
no significant increase in control (Fig. 3.16A and E). I confirmed that salubrinal reduced ER 
stress, both in control and HIHG condition (Fig. 3.16F and G), and demonstrated that ATF6, 
pPERK, and pIRE1 was not changed in control, but decreased in HIHG conditions (Fig. 3.16A, 
B, C and D). 
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Figure 3.16. Salubrinal decreased ER stress and UPR activation in insulin resistant skeletal 
muscle cells.  
(A-E) L6 WT MB were differentiated into MT in 6-well cell culture plates in 2% FBS AMEM, 
starved in 0.5% FBS AMEM for three hours before the 24 hours HIHG treatment + one hour 
salubrinal, or tunicamycin pre-treatment. Upon completion of treatments, cell lysates were 
prepared and protein content analyzed by western blotting. Representative blots are shown 
(A) and quantification of band densitometry is represented as fold over control (B-E; n=3-4) 
with standard error of mean displayed as error bars. 
(F and G) L6 MB were grown on coverslips to 70% confluency in 12-well cell culture plates in 
10% FBS AMEM, starved in 0.5% FBS AMEM for three hours before the 24 hours HIHG 
treatment + one hour salubrinal pre-treatment. ThT assay was performed and 5-9 images per 
condition was taken by fluorescence confocal microscopy. Representative images are shown 
(F) and quantification of total fluorescence/cells is represented as fold over control (G; n=4) 
with standard error of mean displayed as error bars. 
Salubrinal treatment decreased ER stress in both control and HIHG conditions while 
tunicamycin increased ER stress (F and G; P<0.001). peIf2α was increased by salubrinal (A 
and E; p=0.0140). pIRE1, ATF6 and pPERK were increased by HIHG treatment and reduced 
by salubrinal treatment (A, B; p=0.0002, C; p=0.0021, D; p=0.0074).  
(B,C) **Significant difference compared to control, Sal, Sal+HIHG and Tun. (p=0.0002, 
p=0.0021) 
(D) *Significant difference compared to control, Sal, Sal+HIHG and Tun. (p=0.0074)  
(E) *Significant difference compared to control and Sal+HIHG. (p=0.0140)  
(G)* Significant difference compared to control, Sal and Sal+HIHG. # Significant difference 
compared to control and HIHG treatment. (p<0.0001) 
*P < 0.05; **P < 0.01. 
For uncut blots see Appendix A, Supplementary Figure 1. 
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Investigating the effect of salubrinal treatment on autophagy I showed increased TFLC3 
red/green fluorescence in both control and HIHG conditions (Fig. 3.17A and B), and increased 
autophagosome formation, based on increased TFLC3 puncta (Fig. 3.17A) and LC3II (Fig. 
3.17C and D). Salubrinal also decreased lysosomal activity in both control and HIHG conditions 
(Fig. 3.17E).  
 
 
Figure 3.17. Salubrinal increased autophagy.  
(A, B and E) TFLC3 and WT L6 MB were grown on coverslips to 70% confluency in 12-well 
cell culture plates in 10% FBS AMEM, starved in 0.5% FBS AMEM for three hours before the 
24 hours HIHG treatment + one hour salubrinal pre-treatment. TFLC3 L6 MB were fixed upon 
completion of treatment and MagicRed assay was performed on WT L6 MB; 5-9 images per 
condition was taken by fluorescence confocal microscopy. Representative images are shown 
(A and E; n=3-4) and quantification of TFLC3 total red/green fluorescence is represented as 
mean values (B; n=3) with standard error of mean displayed as error bars. 
(C and D) L6 WT MB were differentiated into MT in 6-well cell culture plates in 2% FBS 
AMEM, starved in 0.5% FBS AMEM for three hours before the 24 hours HIHG treatment + 
one hour salubrinal pre-treatment. Upon completion of treatments, cell lysates were prepared 
and protein content analyzed by western blotting. Representative blots are shown (D) and 
quantification of band densitometry is represented as fold over control (E; n=3-4) with 
standard error of mean displayed as error bars. 
Salubrinal increased TFLC3 puncta (A), red/green fluorescence (B; p<0.0001) and LC3II 
levels (C and D; p=0.0243) in both control and HIHG condition and reduced lysosomal activity 
as measured by Cathepsin B and MagicRed assay (E). Tunicamycin also induced autophagy 
and reduced lysosomal activity.   
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(B) *Significant difference compared to control, Sal and Sal+HIHG. ##Significant difference 
compared to control, HIHG and Sal+HIHG treatment. ^Significant difference compared to 
control, HIHG and Sal treatment.  
(D) *Significant difference compared to control and Sal.  
*P < 0.05; **P < 0.01. 
For uncut blots see Appendix A, Supplementary Figure 1. 
 
 
Inducing ER stress with tunicamycin reduced insulin stimulated AKT phosphorylation, 
however alleviating ER stress with salubrinal treatment did not alter AKT phosphorylation in 
control or HIHG conditions (Fig. 3.18A and B). 
 
 
Figure 3.18. Salubrinal treatment did not alter insulin stimulated AKT phosphorylation.  
L6 WT MB were differentiated into MT in 6-well cell culture plates in 2% FBS AMEM, starved 
in 0.5% FBS AMEM for three hours before 24 hours HIHG treatment + one hour salubrinal 
pre-treatment. Upon completion of treatments cells were stimulated with 100nM of insulin for 
5 minutes, cell lysates were subsequently prepared and protein content analyzed by western 
blotting. Representative blots are shown (A) and quantification of band densitometry is 
represented as fold over control (B; n=3) with standard error of mean displayed as error bars. 
Salubrinal did not influence AKT phosphorylation in HIHG or control condition however 
tunicamycin decreased pAKT (A and B; p<0.0001, ANOVA, TPH). 
(B) **Significant difference compared to control and Sal treatment. ##Significant difference 
compared to control and Sal treatment. ^Significant difference compared to control and Sal 
treatment. *P < 0.05; **P. 
For uncut blots see Appendix A, Supplementary Figure 1. 
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3.3.4 ER Stress was Alleviated by Salubrinal in EV but not Atg5K Cells 
 After I showed that salubrinal decreased ER stress (Fig. 3.16) and concurrently 
increased autophagy (Fig. 3.17), I wanted to investigate if the reduction in ER stress was 
dependent on autophagy stimulation. To examine this I compared the ability of salubrinal to 
reduce ER stress in EV compared to Atg5K cells in HIHG condition, demonstrating that that the 
reduction in ER stress observed for EV cells (Fig. 3.19A and C) was not observed for Atg5K 
cells (Fig. 3.19B and D). 
 
 
Figure 3.19.  Salubrinal reduced ER stress in EV but not Atg5K cells.  
L6 EV and Atg5K MB were grown on coverslips to 70% confluency in 12-well cell culture 
plates in 10% FBS AMEM, starved in 0.5% FBS AMEM for three hours before the 24 hours 
HIHG treatment + one hour salubrinal pre-treatment. ThT assay was performed and 5-9 
images per condition was taken by fluorescence confocal microscopy. Representative images 
are shown (A) and quantification of total fluorescence/cells is represented as fold over control 
(B and C; n=4) with standard error of mean displayed as error bars. 
Salubrinal treatment decreased ER stress in HIHG treated EV (A and C; p=0.0147) but not 
ATG5K cells (B and D; p=0.1015). 
(C) *Significant difference compared to control, Sal and Sal+HIHG. *P < 0.05. 
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I further went on to look at proteins involved in autophagy, insulin and UPR signaling and 
how they were regulated by salubrinal in HIHG condition in EV and Atg5K cells. pmTOR was 
unchanged in EV but decreased in Atg5K cells (Fig. 3.20A and B), LC3II was reduced in Atg5K 
compared to EV cells and this was not altered by salubrinal treatment (Fig. 3.20A and C). There 
was no change in pAKT or ATF6 in response to salubrinal treatment in EV or Atg5K cells (Fig. 
3.20A, C and D). pPERK was unchanged in EV cells but showed a decreased trend (p=0.0557) 
in Atg5K cells in response to salubrinal treatment (Fig. 3.20A and F), peIf2α was decreased in 
Atg5K cells but unchanged in EV cells (Fig. 3.20A and G). 
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Figure 3.20. Regulation of the UPR, insulin signaling and autophagy proteins by salubrinal in 
EV and Atg5K cells.  
L6 EV and Atg5K MB were grown to 100% confluence in 6-well cell culture plates in 10% FBS 
AMEM, starved in 0.5% FBS AMEM for three hours before the 24 hours HIHG treatment + 
one hour salubrinal pre-treatment. Upon completion of treatments, cell lysates were prepared 
and protein content analyzed by western blotting. Representative blots are shown (A) and 
quantification of band densitometry is represented as fold over control (B-G; n=2) with 
standard error of mean displayed as error bars.  
Salubrinal decreased pmTOR in Atg5K but not in EV cells (B; p=0.05) however there were no 
increase in LC3II (C; p=0.1613) or pAKT (D; p=0.0039) in response to salubrinal treatment in 
either EV or Atg5K cells. Similarly salubrinal did not change ATF6 (E; p=0.8772) or pPERK 
(F; p=0.2648) in either EV or Atg5K cells. However peIf2α was significantly lowered with 
salubrinal treatment in Atg5K cells (G; p=0.0118). *P < 0.05; **P < 0.01. 
For uncut blots see Appendix A, Supplementary Figure 2. 
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3.3.5 Alleviating Oxidative Stress by NAC Treatment Improved Insulin Sensitivity and Restored 
Autophagy 
 To examine regulation by oxidative stress of cellular processes involved in insulin 
resistance I used NAC treatment, a well-established insulin sensitizer known to alleviate 
oxidative stress, and I confirmed that NAC had an insulin sensitizing effect as measured by its 
ability to improve insulin stimulated AKT phosphorylation in HIHG condition (Fig. 3.21A and B).  
 
 
Figure 3.21. NAC increased insulin stimulated AKT phosphorylation in insulin resistant 
skeletal muscle cells. L6 WT MB were differentiated into MT in 6-well cell culture plates in 2% 
FBS AMEM, starved in 0.5% FBS AMEM for three hours before the 24 hours HIHG treatment 
+ one hour NAC pre-treatment. Upon completion of treatments cells were stimulated with 
100nM of insulin for 5 minutes, cell lysates were subsequently prepared and protein content 
analyzed by western blotting. Representative blots are shown (A) and quantification of band 
densitometry is represented as fold over control (B; n=3) with standard error of mean 
displayed as error bars. 
NAC increased pAKT in HIHG but not in control condition (A and B; p=0.0006).  
(B) *Significant difference compared to control and NAC treatment. #Significant difference 
compared to HIHG and NAC+HIHG. ^Significant difference compared to control. (p=0.0006) 
*P < 0.05. 
For uncut blots see Appendix A, Supplementary Figure 1. 
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Then I investigated the effect of NAC on autophagy and I observed increased TFLC3 
puncta (Fig. 3.22A), increased red/green fluorescence (Fig. 3.22C), but decreased LC3II (Fig. 
3.22D and E), and the increased autophagic flux in response to NAC treatment was associated 
with decreased lysosomal activity (Fig. 3.22B). 
 
 
Figure 3.22. NAC increased autophagy in insulin resistant skeletal muscle cells.  
(A-C) TFLC3 and WT L6 MB were grown on coverslips to 70% confluency in 12-well cell 
culture plates in 10% FBS AMEM, starved in 0.5% FBS AMEM for three hours before 24 
hours HIHG treatment + one hour NAC pre-treatment. TFLC3 L6 MB were fixed upon 
completion of treatment and MagicRed assay was performed on WT L6 MB; 5-9 images per 
condition was taken by fluorescence confocal microscopy. Representative images are shown 
(A and B; n=3) and quantification of TFLC3 total red/green fluorescence is represented as 
mean values (C; n=3) with standard error of mean displayed as error bars. 
(D-E) L6 WT MB were differentiated into MT in 6-well cell culture plates in 2% FBS AMEM, 
starved in 0.5% FBS AMEM for three hours before the 24 hours HIHG treatment + one hour 
NAC pre-treatment. Upon completion of treatments, cell lysates were prepared and protein 
content analyzed by western blotting. Representative blots are shown (D) and quantification 
of band densitometry is represented as fold over control (E; n=4-7) with standard error of 
mean displayed as error bars. 
NAC treatment increased TFLC3 puncta (A) and red/green fluorescence (C; p=0.0040), but 
decreased LC3II in HIHG but not control condition (D and E; p<0.0001). NAC treatment 
increased and lysosomal activity as measured by MagicRed assay (B).  
(C) *Significant difference compared to control, NAC and NAC+HIHG. (p=0.0040) 
(E) *Significant difference compared to control, NAC and NAC+HIHG. #Significant difference 
compared to HIHG and NAC treatment. ^Significant difference compared to control, HIHG 
and NAC. (p=0.0001) 
*P < 0.05; **P < 0.01. 
For uncut blots see Appendix A, Supplementary Figure 1. 
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3.3.6 NAC Downregulated the UPR and Increased ER Stress 
 Interestingly, alleviation of oxidative stress and induction of autophagy was not 
associated with a reduction in ER stress, contrarily NAC treatment increased ER stress (Fig. 
3.23A and B). However KDEL fluorescence was decreased with NAC treatment in HIHG 
condition (Fig. 3.23C), and further, I showed that all three branches of UPR: pIRE1, ATF6 and 
pPERK, and also peIf2α, were decreased in response to NAC treatment in HIHG condition (Fig. 
3.24A-E).  
 
Figure 3.23. NAC treatment increased ER stress.  
L6 MB were grown on coverslips to 70% confluency in 12-well cell culture plates in 10% FBS 
AMEM, starved in 0.5% FBS AMEM for three hours before the 24 hours HIHG treatment + 
one hour NAC pre-treatment. ThT-KDEL co-immunofluorescence assay was performed and 
5-9 images per condition was taken by fluorescence confocal microscopy. Representative 
images are shown (A) and quantification of total fluorescence/cells is represented as fold over 
control (B and C; n=3) with standard error of mean displayed as error bars. 
NAC treatment increased ER stress in control but not HIHG condition (A and B; p=0.0002) 
and decreased KDEL immunofluorescence in HIHG but not control condition (C; p=0.0001). 
(B) **Significant difference compared to Con, NAC and NAC+HIHG. ##Significant difference 
compared to Con and NAC+HIHG. ^Significant difference compared to Con and NAC. 
(p=0.0002) 
(C) *Significant difference compared to Con, NAC and NAC+HIHG. ##Significant difference 
compared to HIHG and NAC+HIHG. ^^Significant difference compared to Con, HIHG and 
NAC. (p=0.0001) 
*P < 0.05; **P < 0.01.  
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Figure 3.24. NAC downregulated UPR signaling in insulin resistant skeletal muscle cells.  
L6 WT MB were differentiated into MT in 6-well cell culture plates in 2% FBS AMEM, starved 
in 0.5% FBS AMEM for three hours before 24 hours HIHG treatment + one hour NAC pre-
treatment. Upon completion of treatments, cell lysates were prepared and protein content 
analyzed by western blotting. Representative blots are shown (A) and quantification of band 
densitometry is represented as fold over control (B-G; n=3-4) with standard error of mean 
displayed as error bars.  
NAC decreased pIRE1, pPERK and ATF6 in HIHG condition but induced no change in control 
condition (A, B, C) while peIf2α was not changed in HIHG or control condition (E). 
(B) **Significant difference compared to Con, NAC and NAC+HIHG (p=0.0010) 
(C) **Significant difference compared to Con, NAC and NAC+HIHG (p=0.0007) 
(D) *Significant difference compared to Con and NAC+HIHG (p=0.0454) 
(E) *Significant difference compared to Con (p=0.0325) 
*P < 0.05; **P < 0.01. 
For uncut blots see Appendix A, Supplementary Figure 1. 
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3.3.7 NAC Treatment Improved Insulin Sensitivity in both EV and Atg5K Cells 
Next I evaluated the importance of autophagy in mediating the insulin sensitizing effect 
of NAC. I compared changes in proteins involved in autophagy, the UPR and insulin signaling in 
EV and Atg5K cells by NAC treatment in HIHG condition. I observed that HIHG treatment in 
Atg5K cells increased pmTOR which was decreased to control levels by NAC treatment (Fig. 
3.25A and B), however NAC also decreased LC3II and increased pAKT in both EV and Atg5K 
cells (Fig. 3.25A, C and D). There was a decreased trend in ATF6 in EV cells (p=0.0860) and in 
pPERK in Atg5K cells (p=0.0566; Fig. 3.25A, E and F), and peIf2α was significantly decreased 
in both EV and Atg5K cells with NAC treatment in HIHG condition (Fig. 3.25A and G). 
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Figure 3.25. Regulation of proteins involved in the UPR, insulin signaling and autophagy in 
HIHG condition by NAC in EV and Atg5K cells.  
L6 EV and Atg5K MB were grown to 100% confluency in 6-well cell culture plates in 10% FBS 
AMEM, starved in 0.5% FBS AMEM for three hours before 24 hours HIHG treatment + one 
hour NAC pre-treatment. Upon completion of treatments, cell lysates were prepared and 
protein content analyzed by western blotting. Representative blots are shown (A) and 
quantification of band densitometry is represented as fold over control (B-G; n=2) with 
standard error of mean displayed as error bars.  
NAC reduced pmTOR in Atg5K but not EV cells (B: p=0.0222) however LC3II was decreased 
in response to NAC treatment in both EV and Atg5K cells (C: p=0.0106). NAC increased 
pAKT in both EV and Atg5K cells (D: p=0.0390), and ATF6 showed a decreased trend in EV 
cells (E: 0.0860) and pPERK showed a decreased trend in Atg5K cells (F: p=0.0566). peIf2α 
was decreased in both EV and Atg5K cells in response to NAC treatment in HIHG condition 
(G: p=0.0122). 
*P < 0.05; **P < 0.01. 
For uncut blots see Appendix A, Supplementary Figure 2. 
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Chapter 4. Discussion 
The staggering increase in obesity prevalence over the last few decades has been 
closely followed by a similar increase in diabetes prevalence, and it is now known that obesity is 
the single most important predictor of developing diabetes with 80% of cases being directly 
related to obesity [7, 8]. Diabetes is a known risk factor for a number of medical conditions and 
thus poses a major and growing health concern [4, 5], and accordingly a lot of research have 
been aimed towards understanding the progression of obesity to diabetes [11, 12]. The hallmark 
of diabetes is insulin resistance and glucose intolerance [1] and, as skeletal muscle is an 
important target for insulin action and a major regulator of whole-body glucose homeostasis, the 
relevance of studying skeletal muscle in the context of insulin resistance is significant [65, 66]; 
firstly, to better understand the complex cellular events involved in the disturbed metabolic 
condition of insulin resistance and diabetes, and secondly, to identify pathways that can be 
potential therapeutic targets. Although skeletal muscle insulin resistance is a well-accepted 
contributor to the pathogenesis of diabetes, the exact molecular mechanisms involved in 
developing insulin resistance in skeletal muscle is not fully known [71] and therefore the first 
objective of my study was to characterize changes in cellular processes and signalling 
responses that exhibited an altered profile in insulin resistant skeletal muscle.  
I started by validating an already established in vitro model of skeletal muscle insulin 
resistance in which L6 skeletal muscle cells were treated with HIHG for 24 hours, resulting in 
impaired insulin signaling and an attenuation of insulin stimulated glucose uptake due to a 
reduction in GLUT4 translocation to the plasma membrane [159]. I confirmed that HIHG 
treatment impaired insulin signaling, and that the impaired insulin signaling resulted in a lack of 
insulin stimulated glucose uptake (Fig. 3.1), and then showed that HIHG treatment impaired 
autophagy (Fig. 3.2), increased ER stress and UPR activation (Fig. 3.4), and caused oxidative 
stress (Fig. 3.7).  
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The adipokine adiponectin have been extensively studied in the context of obesity and 
diabetes but, although adiponectin is well known to have an insulin sensitizing effect in the 
disturbed metabolic profile of those conditions, its cellular mechanism of action remains largely 
unknown, especially in skeletal muscle, [21, 68]. Our lab has recently published that adiponectin 
stimulate autophagy via AMPK and further that adiponectin stimulate expression of genes 
involved in the antioxidant response in skeletal muscle of HFD fed mice [69], however a 
causative relationship between autophagy induction or alleviation of oxidative stress in 
mediating the insulin sensitizing effects of adiponectin still needs to be demonstrated and its 
effect on ER stress and the UPR in skeletal muscle remains to be established. The second 
objective of my study was therefore to further our understanding of the insulin sensitizing 
mechanism of adiponectin in skeletal muscle, examining autophagy, ER stress, the UPR and 
oxidative stress.  
I confirmed that adiponectin treatment improved insulin sensitivity, restored autophagy 
and alleviated ER stress in HIHG treated cells (Fig. 3.8A-F and Fig. 3.10A,C), and I 
demonstrated that the ability of adiponectin to alleviate ER stress in HIHG condition was 
dependent on autophagy using an autophagy deficient cell line, Atg5K (Fig. 3.11A,B,D,E). To 
determine if the insulin sensitizing effect of adiponectin was autophagy dependent I again used 
Atg5K cells, but surprisingly adiponectin was not able to improve insulin sensitivity in either 
Atg5K or EV control cells (Fig. 3.9A,D). However adiponectin treatment did similarly not 
increase autophagy in Atg5K or EV cells (Fig. 3.9C,F), and although HIHG treatment caused 
insulin resistance in Atg5K and EV cells, it increased autophagy in both Atg5K and EV cells, 
contrary to the findings in WT cells (Fig. 3.2A-F and Fig. 3.9A,D,C,F). It is therefore conceivable 
that adiponectin was unable to stimulate autophagy further beyond the increase caused by 
HIHG treatment. No definitive conclusion regarding the necessity of autophagy stimulation in the 
insulin sensitizing effect of adiponectin can be drawn based on the obtained data but the 
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correlation between the ability of adiponectin to induce autophagy and adiponectin’s ability to 
improve insulin sensitivity highlight that this warrants further study.  
Oxidative stress and ER stress have been extensively studied in the context of insulin 
resistance and diabetes, especially in beta-cells, and alleviating ER stress in metabolically 
challenged mouse models has been shown to improve insulin sensitivity and glucose tolerance 
[109-111], and oxidative stress has similarly been shown to be involved in developing insulin 
resistance [171-173] and alleviating oxidative stress has been shown to improve insulin 
sensitivity [174, 175]. Recently there has also been a growing interest in studying the process of 
autophagy in a variety of conditions and disease states including diabetes [176]; it has been 
suggested that dysregulation of autophagy might play an essential role in the progression from 
obesity to diabetes and an increasing body of research is establishing the central role of 
autophagy in regulating whole body metabolism [82]. The relevance of autophagy, ER stress, 
the UPR and oxidative stress in insulin resistance and the close relationship between ER stress, 
the UPR and oxidative stress, that has been suggested to also involve autophagy, makes the 
interrelationship between the processes, especially in the context of insulin resistance, of critical 
importance and examining the relationship between autophagy, ER stress, the UPR and 
oxidative stress in the context of insulin resistance was therefore the third objective of my study.  
Temporal analysis of induction of ER stress, UPR activation and autophagy impairment 
in HIHG induced insulin resistance demonstrated that both insulin signaling and autophagy 
gradually decreased starting somewhere between 0-2 hours, being decreased also at 6 hours 
and further decreased at 24 hours (Fig. 3.1C-D and Fig. 3.3A-B, H-I), while ER stress was 
induced later somewhere between 4-24 hours (Fig. 3.6A, D). Interestingly there was a 
differential activation of the UPR with all three signaling branches of the UPR being activated at 
24 hours (Fig. 3.5A-E and Fig. 3.6B), but with pIRE1 demonstrating a gradual increase at 2, 6 
and 24 hours while pPERK and ATF6 only were increased at 24 hours (Fig. 3.6B).  
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Table 4.1 Summary of time course analysis.  
 
 
 Taken together these data suggests that impaired autophagy or activation of pIRE1 
might be involved in developing insulin resistance while the ER stress observed at 24 hours of 
HIHG treatment is likely to be a concurrent event to the observed insulin resistance, as 
supposed to playing a causative role in its development. Further, since autophagy has been 
demonstrated to alleviate ER stress [99, 100], the impairment in autophagy might directly cause 
the observed increase in ER stress.  
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Figure 4.1.Graphical representation of time course analysis. 
 
 
 
Indeed recently published data from our lab demonstrated that insulin resistance was 
induced both by chemical and molecular impairment of autophagy [69], and to further evaluate 
the role of autophagy in developing insulin resistance and to determine if impaired autophagy 
caused ER stress I directly assessed these processes both in response to chemical inhibition of 
autophagy, by bafilomycin treatment, and in a molecular model of impaired autophagy, Atg5K 
cells. I confirmed previous findings that inhibiting autophagy caused insulin resistance (Fig. 
3.9A,D and Fig. 3.13B,E) and additionally showed that ER stress was increased by both 
chemical and molecular inhibition of autophagy (Fig. 3.13A,C and Fig. 3.14C-F). To further 
investigate if impaired autophagy directly caused ER stress, I inhibited mTOR with rapamycin 
treatment which induced autophagy and also alleviated the ER stress observed in skeletal 
muscle insulin resistance, and the ER stress lowering effects of rapamycin was shown to be 
autophagy dependent (Fig. 3.14A-F). This demonstrated that the impaired autophagy in HIHG 
induced insulin resistance indeed caused ER stress.  
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Looking in detail at proteins that are part of the UPR signaling cascades I observed that 
although all three branches of the UPR, namely pIRE1, pPERK and ATF6, were upregulated in 
response to HIHG treatment, the UPR effector protein immediately downstream of pPERK, 
peIf2α, was decreased. In addition to being an important mediator of the UPR, peIf2α is also 
thought to be a link between UPR activation and autophagy induction making the decrease in 
peIf2α, especially in the context of impaired autophagy, an interesting observation. Temporal 
analysis of peIf2α in progressing insulin resistance revealed that peIf2α showed an early 
increase, at 2 hours, and then gradually decreased, at 6 hours demonstrating similar a level as 
control and at 24 hours being significantly lowered compared to control (Fig. 3.6B and Fig. 
3.5A,E). This pattern in peIf2α can be explained by a self-regulatory mechanism which functions 
to prevent over-activation of peIf2α induced pathways; specifically, activation of peIf2α is known 
to stimulate the expression of GADD34 which dephosphorylates peIf2α to downregulate its 
activity [177]. I observed several instances of a correlation between increased autophagy and 
increased peIf2α, for example in WT cells there was an increase in autophagy in response to 
adiponectin treatment and also an increase in peIf2α (Fig. 3.10E,F) and in both EV and Atg5K 
cells, HIHG treatment increased autophagy and also increased peIf2α (Fig. 3.9C,F and Fig. 
3.11C,H). I thus wanted to examine if, in the context of insulin resistance, directly preventing 
peIf2α dephosphorylation would prevent autophagy impairment and alleviate ER stress, and to 
investigate whether this would improve insulin sensitivity.  
Salubrinal is a well-established pharmacological inhibitor of peIf2α dephosphorylation 
[178], and salubrinal treatment not only restored, but significantly increased autophagy, which 
resulted in a reduction of ER stress (Fig. 3.17A-E and Fig. 3.16F-G). Using Atg5K cells I 
demonstrated that the ER stress lowering effect of salubrinal was dependent on its ability to 
induce autophagy (Fig. 3.19A-D), but despite increasing autophagy and alleviating ER stress 
there was no increase in insulin sensitivity in response to salubrinal treatment (Fig. 3.18A-B). 
These results support that alleviating ER stress is insufficient to improve insulin sensitivity and I 
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speculate that the inability of salubrinal to improve insulin sensitivity, despite also increasing 
autophagy, might be caused by the induction of autophagy surpassing normal levels as both too 
much and too little autophagy is known to be detrimental [127] highlighting the importance of 
properly regulated autophagy in maintaining cellular homeostasis or, alternatively, that 
increased peIf2α in addition to stimulating autophagy also causes cells cycle arrest and 
increases ER stress induced apoptotic signaling [179] potentially perpetrating cellular 
dysregulation and an insulin resistant state. Interestingly, although alleviating ER stress does 
not improve insulin sensitivity in skeletal muscle insulin resistance, increasing ER stress by 
tunicamycin treatment (Fig. 3.16F) did cause insulin resistance (Fig. 3.18A,B), but also 
increased autophagy (Fig. 3.17A,C-E). 
To determine which of the aforementioned processes are required for insulin 
sensitization I wanted to examine them in response to NAC, an antioxidant that has been 
demonstrated to improve insulin sensitivity [118]. While I confirmed the insulin sensitizing effect 
of NAC in skeletal muscle (Fig. 3.21A,B), I also demonstrated a clear increase in ER stress in 
response to NAC treatment (Fig. 3.23A,B). This further evidences that alleviating ER stress is 
insufficient to improve insulin sensitivity and does not appear to even be required to combat 
insulin resistance, and that insulin resistance observed in response to tunicamycin treatment is 
likely caused by a secondary event to ER stress and not the ER stress itself. I also showed that 
NAC treatment increased autophagy in skeletal muscle insulin resistance (Fig. 3.22A-E) 
however examining the effect of NAC in Atg5K cells I demonstrated that this increase in 
autophagy was not required for the insulin sensitizing effect of NAC (Fig. 3.25A,D).  
Examining the regulation of the UPR in response to NAC treatment I observed a clear 
decrease in activation of all three UPR signaling proteins, and also peIf2α, in WT cells (Fig. 
3.24A-E) with similar trends observed also in EV and Atg5K cells (Fig. 3.24A, E-G). As 
activation of the UPR, specifically pIRE1, has been linked to phosphorylation of JNK and 
impaired insulin signaling [112, 180] this is an interesting observation.  
73 
Looking at the regulation of UPR signaling proteins in response to other treatments we 
can see that there appears to be a trend correlation between reducing UPR signaling and 
improving insulin sensitivity. For example in response to adiponectin treatment there was a 
decreased trend, significant for ATF6, in the UPR signaling proteins (except peIf2α; Fig. 3.10C-
H), and in Atg5K and EV cells adiponectin did not alter ATF6 or pPERK or peIf2α, consistent 
with its inability to improve insulin sensitivity (Fig. 3.11C,F-H). Rapamycin increased insulin 
sensitivity in Atg5K but not EV cells, again correlating with a decreased trend in UPR signaling 
in Atg5K but not EV cells (Fig. 3.15A,D-G) although the regulation of pIRE1 still needs to be 
examined. Interestingly in response to salubrinal treatment there was a small increased trend in 
insulin sensitivity in Atg5K cells which correlated with a decreased trend in UPR signaling, a 
significant decrease in peIf2α and a decrease in autophagy (Fig. 3.20A,D-G).  
These results point to a very complex network being involved in improving insulin 
sensitivity and highlight the importance of a balanced regulation. It is conceivable that all of 
these processes are involved in different pathways resulting in increased insulin sensitivity, 
although a close relationship appears to exist between autophagy, oxidative stress and the 
UPR, and cumulatively these results point to a reduction in UPR activation being the common 
denominator between the ability of adiponectin, NAC and rapamycin to have an insulin 
sensitizing effect. 
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 Figure 4.2. Summary of the interrelationship between autophagy, ER stress, the UPR and 
oxidative stress in skeletal muscle insulin resistance and regulation by adiponectin. HIHG 
treatment increased pmTOR and impaired autophagy leading ER stress, UPR activation and 
insulin resistance; HIHG treatment also caused oxidative stress which further exacerbate 
dysregulation of cellular homeostasis leading to ER stress, UPR activation and insulin 
resistance. Chemical or molecular impairment of autophagy and induction of ER stress was 
associated with insulin resistance but alleviating ER stress or inducing autophagy was not 
necessary to improve insulin sensitivity by NAC treatment, although adiponectin’s insulin 
sensitizing ability appeared to correlate with its ability to induce autophagy. Correlations 
between improved insulin sensitivity and downregulated UPR signalling suggests its 
importance in regulation of insulin resistance, potentially via JNK.    
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In summary, skeletal muscle insulin resistance is associated with impaired autophagy, 
ER stress, increased UPR activation and oxidative stress. Chemical and molecular inhibition of 
autophagy leads to insulin resistance and chemical inhibition of protein folding to increase ER 
stress also caused insulin resistance, however temporal analysis revealed that impaired 
autophagy is an early event while ER stress happened later, and I have demonstrated that the 
ER stress in insulin resistance was directly caused by the impairment of autophagy.  
Although impairment in autophagy followed a similar pattern as developing insulin 
resistance and demonstrated a correlation with the ability of adiponectin to improve insulin 
sensitivity it was not required for the antioxidant NAC to improve insulin sensitivity, and 
correlations between improved insulin sensitivity and downregulation of the UPR point to this 
potentially being the converging point between several cellular processes and regulation of 
insulin sensitivity.  
Future studies should examine oxidative stress in the context of skeletal muscle insulin 
resistance, both by temporal analysis and in response to adiponectin and chemical and 
molecular regulators of autophagy and ER stress, to help clearly place it in relationship to these 
processes in the context of skeletal muscle insulin resistance. Future studies should also aim to 
determine if autophagy is required for the insulin sensitizing properties of adiponectin, if there is 
a significant correlation between a reduction in UPR and improved insulin sensitivity in response 
to adiponectin and rapamycin treatment, particularly in pIRE1, and examine whether activation 
of JNK correlates with these changes thus clearly linking the regulation of UPR activation by 
autophagy and oxidative stress with insulin resistance.  
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Appendix A: Supplementary Figures 
 
 
Supplementary Figure 1. Uncut blots showing the regulation by adiponectin, NAC, salubrinal, 
bafilomycin and tunicamycin of proteins involved in the UPR, insulin signaling and autophagy 
in control and HIHG condition in WT MT L6 cells. Representative blots previously shown in 
Figure 3.10 (B; lane 1-4), Figure 3.12 (A; lane 1-2, 9-10), Figure 3.13 (C; lane 1-2, 9-10), 
Figure 3.16 (B; lane 1-2, 7-8, 11), Figure 3.17 (A; lane 1-2, 7-8, 11), Figure 3.18 (C; lane 1-2, 
7-8, 11), Figure 3.21 (C; lane 1-2, 5-6), Figure 3.22 (A; lane 1-2, 5-6) and Figure 3.24 (B; lane 
1-2, 5-6). 
 
 
 
Supplementary Figure 2. Uncut blots showing the regulation by adiponectin, NAC, salubrinal, 
and rapamycin of proteins involved in the UPR, insulin signaling and autophagy in HIHG 
condition compared to control in EV and Atg5K MB L6 cells. Representative blots previously 
shown in Figure 3.9 (B; lane 1-6), Figure 3.11 (A; lane 1-6), Figure 3.15 (A and B; lane 3-4, 
11-12), Figure 3.20 (A and B; lane 3-4, 9-10) and Figure 3.25 (A and B; lane 3-4, 7-8). 
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Appendix B: List of Contributions 
The thesis was researched and written by Penny Ahlstrom (P.A.) who helped plan experiments 
and develop protocols; P.A. also performed the majority of the experimental work. P.A. worked 
with Suharto Chakma (S.C.) and while P.A. trained S.C. in cellular and molecular assays he 
contributed to some of the experimental work. An account of contributions by S.C. are listed as 
follows. Note that when no specification are detailed P.A. performed all the experimental work.  
Chapter 3. Results 
Figure 3.1 (A) S.C. re-ran samples for representative blots. 
Figure 3.3 (A) S.C. prepared fluorescence microscopy slides, took some representative 
images and helped with quantification. 
Figure 3.6 (C-E) S.C. prepared fluorescence microscopy slides for 4 hours HIHG treatment, 
took representative images and helped with quantification.  
Figure 3.9 (A-F) S.C. developed beta-actin blots.        
Figure 3.11 (A-H) S.C. developed beta-actin blots.     
Figure 3.14 (A) S.C. prepared fluorescence microscopy slides, took some representative 
images and helped with quantification.    
Figure 3.15 (A-G) S.C. developed beta-actin blots.           
Figure 3.20 (A-G) S.C. developed beta-actin blots.        
Figure 3.25 (A-G) S.C. developed beta-actin blots.      
Appendix A: Supplementary Figures 
      Supplementary Figure 2. (A-B) S.C. developed beta-actin blots.      
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